$154.55
+2.58 (+1.70%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NVS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
Of the 500 shown: 472 interventional · 27 observational · 1 expanded access · 194 with posted results
Held by 21 tracked-famous managers (PRIMECAP MANAGEMENT CO/CA/, Holocene Advisors, LP, RENAISSANCE TECHNOLOGIES LLC, Dodge & Cox, MILLENNIUM MANAGEMENT LLC, +16 more) · FINRA short interest 2.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult PatientsNCT06595069observationalPercentage Change From Baseline to Month 9 in Low Density Lipoprotein Cholesterol (LDL-C) Levels | — | Completed | — | Hypercholesterolemia | 600 | 2024-07-10actual | 2024-09-19 |
| Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 TherapiesNCT06526000observationalPercentage Change per Year in Immunoglobulin G (IgG) Levels in Patients Receiving Ocrelizumab | — | Completed | — | Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | 326 | 2024-02-28actual | 2024-07-29 |
| Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery RegistryNCT06662812observationalNumber of Patients in the Globin Research Network for Data and Discovery (GRNDaD) Registry who Received a Disease Modifying Therapy (DMT) | — | Completed | — | Sickle Cell Disease | 1,665 | 2023-12-01actual | 2024-10-29 |
| A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or AlpelisibNCT06705504observationalReal-world Progression-free Survival (rwPFS) | — | Completed | — | Hormone Receptor Positive HER-2 Negative Breast Cancer | 435 | 2023-11-30actual | 2024-11-26 |
| Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in SpainNCT06632730observationalCost per Year of Use of Resources for Medical Visits | — | Completed | — | Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II | 69 | 2023-11-20actual | 2024-10-09 |
| Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV MelanomaNCT06557291observationalRelapse-free Survival-2 (RFS-2) | — | Completed | — | BRAF V600 Mutated-Stage III/IV Melanoma | 38 | 2023-11-16actual | 2024-08-16 |
| Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell CentersNCT06662825observationalAge at Index Date | — | Completed | — | Sickle Cell Disease | 376 | 2023-11-01actual | 2024-10-29 |
| Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple SclerosisNCT06644638observationalNumber of Patients Persistent on Ofatumumab and Self-injectable Disease-modifying Therapies (DMTs) | — | Completed | — | Multiple Sclerosis | 3,632 | 2023-10-30actual | 2024-10-16 |
| Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With AsciminibNCT06516029observationalAge at Index Date | — | Completed | — | Chronic Myeloid Leukemia, Chronic Phase | 111 | 2023-10-02actual | 2024-07-23 |
| A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple SclerosisNCT06588387observationalNumber of Patients by Education Status | — | Completed | — | Secondary Progressive Multiple Sclerosis | 210 | 2023-09-08actual | 2024-09-19 |
| A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple SclerosisNCT06395909observationalAnnualized Relapse Rate (ARR) | — | Completed | — | Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | 113 | 2023-08-31actual | 2024-05-02 |
| Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims DatabaseNCT06600009observationalNumber of Patients with Persistence of Secukinumab Treatment at One Year | — | Completed | Drug: Secukinumab, Adalimumab | Psoriatic Arthritis | 534 | 2023-08-21actual | 2024-09-19 |
| A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial HypercholesterolemiaNCT06507852observationalPercentage of Patients who Received Inclisiran Dose 2 and 3 Within Specified Time Intervals | — | Completed | — | Atherosclerotic Cardiovascular Disease, Hypercholesterolemia | 95 | 2023-07-06actual | 2024-07-18 |
| Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL StudyNCT06463626observationalMean Age | — | Completed | — | Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | 121 | 2023-06-27actual | 2024-06-18 |
| Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma PatientsNCT06369428observationalMean Age-standardized Annual Incidence of Metastatic Melanoma in 2014-2021 | — | Completed | — | Metastatic Melanoma | 1,795 | 2023-04-13actual | 2024-04-17 |
| Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection FractionNCT06671314observationalTime Spent 30 Days Post-discharge by Discharge Sacubitril/Valsartan (SAC/VAL) Prescription Status | — | Completed | — | Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction | 42,494 | 2022-10-31actual | 2024-11-04 |
| Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying TherapiesNCT06459232observationalNumber of Patients with a Minimum of 6 Months Follow-up by Disease-Modifying Therapy (DMT) Use | — | Completed | — | Multiple Sclerosis | 143 | 2021-12-17actual | 2024-06-14 |
| Drug Use Investigation for TYKERB Tablet (All Case Investigation)NCT01332396observationalThe incidence of adverse events in Japanese patients treated with TYKERB based on prescribing information under the conditions of general clinical practice | — | Completed | Drug: Lapatinib | Cancer | 4,054 | 2017-03-13actual | 2017-04-26 |
| Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple MyelomaNCT01428492The recommended Phase II dose (RP2D) and schedule of GSK2110183, bortezomib and dexamethasone dosed in combination.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: GSK2110183, Bortezomib, Dexamethasone | Multiple Myeloma | 90 | Oct 2015actual | 2018-08-08 |
| A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)NCT02235740Part1: Number of participants with adverse events (AEs) as a measure of safetyRandomized · Open-label · Treatment | Phase 1 | Terminated | Drug: Afuresertib, Carfilzomib | Cancer | 1 | Oct 2015actual | 2016-05-04 |
| Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma InjuriesNCT02290821results2017-04-19Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: placebo, Placebos | Acute Blunt Soft Tissue Injuries/Contusions | 215 | Sep 2015actual | 2017-04-19 |
| Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and FluNCT01448057results2017-01-13Physician Global Evaluation of Effectiveness on Nasal SymptomsRandomized · Single-masked · Treatment | Phase 3 | Completed | Drug: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets, Paracetamol (500 mg) tablets | Upper Respiratory Tract Infection, Nasal Congestion, Rhinorrhea, Sneezing | 341 | Aug 2015actual | 2017-03-03 |
| Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Infants Aged Less Than 90 DaysNCT02099149observationalEarly onset Group B Streptococcus Disease due to serotypes Ia or III | — | Withdrawn | — | Invasive Group B Streptococcus Disease | 0 | Aug 2015 | 2014-07-24 |
| Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE StudiesNCT01715779observationalMortality. Patients who experience a thromboembolic event (TEE) and died during study participation. | — | Completed | Drug: Eltrombopag | Hepatitis C | 22 | Jun 2015actual | 2016-04-08 |
| Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)NCT02382913results2016-02-12Geometric Mean Concentrations (GMCs) of Antibodies in aP1, aP2, aP4 Groups Against Pertussis Antigens at Day 1.Randomized · Open-label | Phase 1 | Completed | Biological: aP booster, TdaP booster, Licensed TdaP booster (Boostrix®) | Pertussis | 315 | Jun 2015actual | 2016-03-24 |
| A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.NCT02427750results2015-10-19Percentages of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm^2, Against Each of Three Vaccine Strains After Receiving One Dose of TIV.Open-label · Prevention | Phase 2 | Completed | Biological: Aggripal® | Human Influenza | 126 | May 2015actual | 2015-10-19 |
| Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.NCT02305446results2015-11-02Number of Subjects Reporting Unsolicited Adverse Events (AEs).Open-label · Prevention | Phase 3 | Completed | Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine | Meningitis, Meningococcal, Serogroup B | 55 | Apr 2015actual | 2016-01-05 |
| Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and CoughNCT02379637results2016-07-11Cough Count (Number of Coughs Will be Measured by a 24-hour Ambulatory Cough Monitoring System for the First 72 Hours)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: N-acetylcysteine, Placebo | Common Cold Associated With Cough | 70 | Apr 2015actual | 2016-07-11 |
| EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast CancerNCT00338247expanded access | — | Approved for marketing | Drug: lapatinib + capecitabine | Neoplasms, Breast | — | Mar 2015actual | 2016-04-06 |
| Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.NCT02141516results2017-02-15Percentages of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) Titers ≥ 5 for B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain.Non-randomized · Open-label · Prevention | Phase 3 | Completed | Biological: rMenB+OMV, rMenB+OMV, rMenB+OMV | Meningococcal Disease | 239 | Mar 2015actual | 2017-02-15 |
| A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle SorenessNCT02271854results2016-04-05Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW.Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Diclofenac sodium gel 1%, Placebo | Muscle Soreness | 102 | Dec 2014actual | 2016-04-05 |
| Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of AgeNCT02177032results2017-04-07Percentages of Subjects With RVNA Titer >= 0.5 and Vaccine Group Differences ("4-sites, 1-week" to That of "2-sites, TRC" ID PEP Regimen of the PCEC Rabies Vaccine With or Without HRIG Administration)Randomized · Open-label · Prevention | Phase 3 | Completed | Biological: Rabies vaccine, Rabies vaccines + Rabies immunoglobulins, Rabies vaccine, Rabies vaccines + Rabies immunoglobulins | Rabies Infection | 885 | Oct 2014actual | 2017-04-07 |
| A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) PatientsNCT01220115observationalDocument current treatment patterns, natural history and outcomes in patients with sickle cell disease | — | Completed | — | Sickle Cell Disease | 498 | Sep 2014actual | 2019-12-09 |
| Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of MigraineNCT01973205results2015-06-11Number of Subjects Who Are Pain Free at the 2-hour AssessmentRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Acetaminophen 250 mg and Aspirin 250 mg, Placebo | Acute Migraine | 900 | Jul 2014actual | 2015-06-11 |
| Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)NCT01967550results2015-06-03Measure: Pain On Movement (POM)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: diclofenac diethylamine, DDEA 2.32% gel, Placebo | Osteoarthritis, Knee | 304 | May 2014actual | 2015-06-03 |
| Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in IndiaNCT01547715results2014-12-31Percentages of Subjects With Human Serum Bactericidal Assay (hSBA) Seroresponse Against N.Meningitidis Serogroup A.Non-randomized · Open-label · Prevention | Phase 3 | Completed | Biological: Meningococcal ACWY conjugate vaccine | Bacterial Meningitis | 180 | Apr 2014actual | 2018-10-09 |
| Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and AboveNCT01867021results2014-10-01Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) of TIV Group and TIVf Group for All Three Strains, in Healthy Adults Aged ≥50 YearsRandomized · Quadruple-masked · Prevention | Phase 4 | Completed | Biological: Fluvirin(TIVf), Agriflu (TIV) | Influenza | 2,902 | Dec 2013actual | 2014-10-01 |
| Retrospective Study of Long-term Survival and Related Factors Among Kidney Transplant Recipients in ChinaNCT01796639observationalGraft survival | — | Completed | — | Kidney Transplantation | 1,500 | Aug 2013actual | 2014-06-18 |
| Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)NCT01160094observationalTime to disease progression | — | Completed | Drug: Treatment | Cancer | 288 | Jul 2013actual | 2016-03-28 |
| Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their OffspringsNCT01446289results2014-09-08Geometric Mean Concentrations (GMCs) of Antibodies in Mothers and Infants at Delivery/BirthRandomized · Single-masked · Prevention | Phase 2 | Completed | Biological: Group B Streptococcus Trivalent Vaccine, Placebo | Streptococcal Infection, Gram-positive Bacterial Infection, Bacterial Infection | 86 | Apr 2013actual | 2014-09-08 |
| Efficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint PainNCT01666197results2014-03-27Pain on MovementRandomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: diclofenac potassium 25 mg tablet, placebo | Ankle Sprain | 100 | Jan 2013actual | 2014-04-17 |
| A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in AdolescentsNCT01424644results2014-02-14Percentages of Subjects With Anti-diphtheria and Anti-tetanus Antibody Concentrations ≥ 0.1 IU/mL When Tdap is Administered Concomitantly With HPV and MenACWY-CRM Vaccine Compared to Tdap Given Concomitantly With HPV and PlaceboRandomized · Double-masked · Prevention | Phase 4 | Completed | Biological: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine | Meningococcal Meningitis | 801 | Dec 2012actual | 2014-02-14 |
| Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy ToddlersNCT01434680results2014-03-26Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup C 28 Days After VaccinationRandomized · Single-masked · Prevention | Phase 2 | Completed | Biological: MenC-CRM LIQ, MenC-CRM ROS, MenC-CRM EMV | Meningococcal Disease, Meningococcal Meningitis | 992 | Nov 2012actual | 2017-04-25 |
| Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and InfantsNCT01437267results2014-04-10Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) TiterRandomized · Quadruple-masked · Prevention | Phase 2 | Completed | Biological: Vi-CRM197 vaccine, Pneumococcal conjugate vaccine, Vi Polysaccharide (PS) vaccine | Typhoid Fever | 120 | Aug 2012actual | 2014-04-10 |
| Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.NCT01023815results2013-11-14Treatment Failure RateRandomized · Open-label · Prevention | Phase 3 | Completed | Drug: everolimus, cyclosporine, Prednison (continuous steroids) | de Novo Kidney Transplant Recipients, Renal Transplantation | 330 | Jul 2012actual | 2016-07-19 |
| A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)NCT01256658results2013-11-25Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Infants and Children (<5 Years) in Post Community Screening Campaign (CSC) at Month 12 (Per Cluster)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: COA566 | Malaria | 14,075 | Jul 2012actual | 2014-02-10 |
| Long Term Study of Fingolimod in MS Patients From the FTY Clinical ProgramNCT01281657observationalLong-term safety data in patients with relapsing forms of multiple sclerosis who have participated in clinical trials with fingolimod and who are now taking prescribed fingolimod under the conditions of routine medical practice | — | Completed | Drug: fingolimod | Multiple Sclerosis | 64 | Jul 2012actual | 2012-09-06 |
| Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® BirchNCT01902992Combined Symptom and Medication Score (SMS)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Depiquick Birch (DPG103), Placebo | Allergic Rhinoconjunctivitis | 202 | Jul 2012actual | 2017-03-22 |
| Zoledronic Acid in MS-patients With OsteoporosisNCT01166178results2013-11-26Change in Bone Mineral Density of the Lumbar Spine at 12 MonthsRandomized · Quadruple-masked · Treatment | Phase 3 | Terminated | Drug: Zoledronic Acid, Placebo · Dietary supplement: Calcium and Vitamin D combination | Osteoporosis, Multiple Sclerosis | 29 | Jun 2012actual | 2013-11-26 |
| Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and InfantsNCT01229176results2014-04-10Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) TiterRandomized · Single-masked · Prevention | Phase 2 | Completed | Biological: Vi-CRM197 vaccine, Vi Polysaccharide (PS) vaccine, Pneumococcal conjugate vaccine | Typhoid Fever | 200 | Jun 2012actual | 2014-05-01 |
| Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized RegimenNCT01037348The difference from baseline in mean Best Corrected Visual Acuity (BCVA)Open-label · Treatment | Phase 2 | Completed | Drug: ranibizumab 0.5mg | Choroidal Neovascularisation | 65 | May 2012actual | 2016-04-19 |
| Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI)NCT01576809results2013-11-11Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Per 30 ml SyrupOpen-label | Phase 3 | Completed | Drug: IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin | Upper Respiratory Infections | 51 | May 2012actual | 2013-11-11 |
| Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTINCT01586962results2013-08-07Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Pseudoephedrine 30 mg Per 30 ml SyrupOpen-label | Phase 3 | Completed | Drug: IFF flavor 316 282, Paracetamol, Pseudoephedrine | Upper Respiratory Infections | 56 | May 2012actual | 2013-08-07 |
| An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple SclerosisNCT00670449results2013-09-04Percentage of Patients Free of Gd-enhanced T1 Weighted Magnetic Resonance Imaging (MRI) LesionsRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Fingolimod | Multiple Sclerosis | 143 | Apr 2012actual | 2013-09-04 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in AdultsNCT01466387results2014-03-11Geometric Mean Anti-typhoid Vi Antibody ConcentrationsRandomized · Open-label · Prevention | Phase 3 | Completed | Biological: Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine, Rabies Vaccine, MenACWY-CRM Vaccine | Meningococcal Disease, Meningococcal Meningitis, Typhoid, Yellow Fever, Rabies, Japanese Encephalitis | 552 | Apr 2012actual | 2014-03-11 |
| Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With HypertensionNCT00498433results2013-10-24Part 1: Aliskiren Concentrations From Interstitial Fluid (Microdialysis)at the End of Aliskiren Treatment PeriodRandomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Early termination resulted from interim analysis of the ALTITUDE trial | Drug: Aliskiren, Amlodipine, Placebo of Aliskiren, Placebo of amlodipine | Hypertension, Abdominal Obesity | 46 | Mar 2012actual | 2014-09-10 |
| To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's PatientsNCT01023685Safety/tolerability assessments at multiple time points including but not limited to screening, and through to the end of the study to week 66.Non-randomized · Open-label · Treatment | Phase 2 | Completed | Biological: CAD106 | Alzheimer Disease | 24 | Feb 2012actual | 2020-12-17 |
| Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea PedisNCT01433107results2013-12-27Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Terbinafine, Terbinafine Placebo | Tinea Pedis | 290 | Feb 2012actual | 2013-12-27 |
| Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44NCT00948766results2013-02-11Core Study: Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24Randomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2), Placebo | Alzheimer's Disease | 716 | Jan 2012actual | 2013-08-28 |
| Switching to Iloperidone From Other Antipsychotics in SchizophreniaNCT01207414results2013-03-15Integrated Clinical Global Impression of Change (I-CGI-C) at Week 12Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: iloperidone | Schizophrenia | 501 | Jan 2012actual | 2013-03-15 |
| Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in TaiwanNCT01410474results2014-09-22Percentage of Overall Subjects With Seroresponse, Directed Against Neisseria Meningitidis Serogroups A, C, W and Y After MenACWY-CRM VaccinationNon-randomized · Open-label · Prevention | Phase 3 | Completed | Biological: Meningococcal ACWY conjugate vaccine | Bacterial Meningitis | 341 | Jan 2012actual | 2014-09-22 |
| A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal TherapyNCT00639691Serious Adverse Events from first visit until end of studyOpen-label · Treatment | Phase 4 | Completed | Biological: omalizumab | Asthma | 48 | Dec 2011actual | 2016-09-29 |
| Phase 4 Study in the Elderly Patients With T2DMNCT01238978Percent of patients in each of the two treatment groups presenting no hypoglycemia (confirmed events with SMBG and severe episodes) after 24 wk of randomized therapy added to their ongoing metformin background therapy.Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Vildagliptin, "Usual Care" | Type 2 Diabetes Mellitus, Elderly | 46 | Dec 2011actual | 2017-02-23 |
| Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 YearsNCT01423084results2015-02-20Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against 3 Neisseria.Meningitidis (N. Meningitidis) Serogroup B Reference Strains.Randomized · Quadruple-masked · Prevention | Phase 3 | Completed | Biological: Serogroup B meningococcal vaccine | Meningococcal Disease, Meningococcal Meningitis | 344 | Dec 2011actual | 2015-02-20 |
| Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in AdultsNCT01438996results2014-03-24Anti-Vi ELISA Geometric Mean Concentration (GMC)Non-randomized · Open-label · Prevention | Phase 2 | Completed | Biological: NVGH Vi-CRM197 | Typhoid Fever | 51 | Dec 2011actual | 2014-03-24 |
| Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus GlimepirideNCT01233622HbA1c ReductionRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Vildagliptin, Placebo | Type 2 Diabetes Mellitus | 317 | Nov 2011actual | 2017-02-23 |
| Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes MellitusNCT00927394results2012-10-31Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan | Hypertension | 1,143 | Oct 2011actual | 2012-12-06 |
| A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.NCT01056731The proportion of patients in whom BP control was achieved at the study end pointOpen-label · Treatment | Phase 4 | Completed | Drug: Aliskiren and HCTZ | High Blood Pressure | 253 | Oct 2011actual | 2017-02-23 |
| Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) PatientsNCT01127750Evaluate the safety and tolerability profile of FTY720 in patients with relapsing forms of MSOpen-label · Treatment | Phase 3 | Completed | Drug: FTY720 | Relapsing Multiple Sclerosis | 2,417 | Oct 2011actual | 2017-02-23 |
| Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)NCT01196546HbA1c reductionOpen-label · Treatment | Phase 4 | Completed | Drug: vildagliptin/metformin | Type 2 Diabetes Mellitus | 161 | Oct 2011actual | 2017-08-01 |
| Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes MellitusNCT01224366HbA1c reductionRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Vildagliptin, Placebo | Type 2 Diabetes Mellitus | 448 | Oct 2011actual | 2017-02-23 |
| Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCINCT00406016Feasibility, Safety and Tolerability of a continuous intrathecal (i.t.) infusion or i.t. repeated bolus injections of ATI355 in patients with acute spinal cord injury at every visit and Assessment of serum and CSF pharmacokinetics at predefined visits.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ATI355 | Acute Spinal Cord Injury | 52 | Sep 2011actual | 2020-02-11 |
| Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron OverloadNCT00673608Change in cardiac iron load and cardiac ejection fraction by MRI recorded at baseline and after 53 weeks.Open-label · Treatment | Phase 4 | Completed | Drug: deferasirox | Hemoglobinopathies, Myelodysplastic Syndromes, Other Inherited or Acquired Anaemia, MPD Syndrome, Diamond-Blackfan Anemia, Other Rare Anaemias, Transfusional Iron Overload | 118 | Sep 2011actual | 2017-02-23 |
| Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset SeizuresNCT01147003To detect a dose-response by measuring the percent change in seizure frequency of BGG492 from baseline to maintenance period.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Investigational new drug, company code: BGG492, Placebo, Investigational new drug, company code: BGG492 | Partial Onset Seizures | 93 | Sep 2011actual | 2020-12-17 |
| Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular EdemaNCT00989989results2012-10-18Average Change From Baseline of Best-Corrected Visual Acuity (BCVA) Over 12 Months (From Month 1 to Month 12 Compared to Baseline)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Ranibizumab, Sham ranibizumab · Procedure: Laser photocoagulation, Sham laser photocoagulation | Diabetic Macular Edema | 396 | Aug 2011actual | 2012-10-18 |
| Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Ankle SprainNCT01272934results2013-01-15Pain on MovementRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Diclofenac Sodium · Other: Placebo | Acute Ankle Sprain | 205 | Aug 2011actual | 2013-01-24 |
| Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension PhaseNCT00340834results2011-05-16Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the StudyRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg | Multiple Sclerosis | 1,292 | Jul 2011actual | 2017-09-21 |
| Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced DyskinesiaNCT01092065Change from baseline to the last-observation-carried-forward (LOCF) endpoint at week 5 in total OFF time collected from the Hauser et al. patient diaryRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: AFQ056 with L-dopa, Placebo | Parkinson's Disease | 23 | Jul 2011actual | 2020-12-23 |
| Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Blunt Trauma InjuriesNCT01272947results2013-01-10Pain on MovementRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Diclofenac sodium · Other: Placebo | Acute Blunt Soft Tissue Injuries/Contusions | 204 | Jul 2011actual | 2013-01-10 |
| Efficacy and Safety of Diclofenac 1.16% Gel in Subjects With Acute Neck PainNCT01335724results2012-07-18Pain on MovementRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Diclofenac diethylamine 1.16% gel, Placebo gel | Neck Pain | 72 | Jul 2011actual | 2012-07-18 |
| Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisNCT00355134results2012-06-26Aggregate Annualized Relapse Rate (ARR) Estimate up to Month 24Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Fingolimod, Placebo | Multiple Sclerosis | 1,083 | Jun 2011actual | 2012-08-07 |
| Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisNCT00662649results2012-07-12Annualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Fingolimod 0.5 mg, Fingolimod 1.25 mg | Multiple Sclerosis | 920 | Jun 2011actual | 2012-07-12 |
| To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's PatientsNCT00956410Safety/tolerability assessments at multiple timepoints including but not limited to screening, and through to the end of the study to week 66.Non-randomized · Open-label · Treatment | Phase 2 | Completed | Biological: CAD106 | Alzheimer Disease | 21 | Jun 2011actual | 2020-02-11 |
| Glycemic Holter Study (Continuous Glucose Monitoring) -NCT01193296Glycemic variability assessed by MAGE (Mean Amplitude of Glycemic Excursion)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Vildagliptin, Sitagliptin | Type 2 Diabetes Mellitus | 36 | Jun 2011actual | 2012-05-04 |
| Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle SprainNCT01255423results2012-10-04Pain on MovementRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Diclofenac sodium topical gel 1%, Placebo | Ankle Sprain | 206 | Jun 2011actual | 2012-10-04 |
| Real-world Aliskiren Use in Diabetic PatientsNCT01393860observationalMeasure: Change in blood pressure | — | Completed | — | Diabetes, Hypertension | 200 | Jun 2011actual | 2011-07-14 |
| Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)NCT01199861results2012-06-19Immune Response 3 Weeks After Seasonal Influenza VaccinationRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Fingolimod, Placebo · Biological: Seasonal influenza vaccine, Tetanus toxoid vaccine | Relapsing Multiple Sclerosis | 138 | May 2011actual | 2012-06-19 |
| Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential HypertensionNCT01237223results2012-06-13Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Aliskiren/Amlodipine 150/2.5 mg, Aliskiren/amlodipine 150/5 mg, Aliskiren 150 mg, Amlodipine 2.5 mg, Placebo of Aliskiren, Placebo of Amlodipine, Placebo of Aliskiren/amlodipine 150/2.5 mg, Placebo of Aliskiren/amlodipine 150/5 mg | Essential Hypertension | 1,342 | May 2011actual | 2012-06-13 |
| Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant PatientsNCT01256294results2012-06-21Dose-Normalized Area Under the Concentration-time Curve From Time 0 to 12 Hours (AUC0-12h) at Steady StateRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Generic Tacrolimus, Branded Tacrolimus | Renal Transplant | 71 | May 2011actual | 2012-06-21 |
| Efficacy and Safety of FTY720 in Patients With Relapsing Multiple SclerosisNCT00333138results2012-10-30Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 6 (Core)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: FTY720, Placebo | Multiple Sclerosis | 281 | Apr 2011actual | 2017-09-15 |
| Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)NCT00765830To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 52 weeks of treatmentRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: vildagliptin, Placebo | Diabetes Mellitus, Type 2, Renal Insufficiency | 349 | Apr 2011actual | 2020-12-17 |
| Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)NCT00770081Assessment of treatment emergent adverse events (including hypoglycemia events and other events of special interest)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: vildagliptin, sitagliptin | Diabetes Mellitus, Type 2, Renal Insufficiency | 75 | Apr 2011actual | 2020-12-17 |
| 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)NCT00929110results2012-07-27Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium | Chronic Obstructive Pulmonary Disease | 1,066 | Apr 2011actual | 2012-08-17 |
| Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive PatientsNCT01167153results2012-06-01Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at the Study End Point (12 Weeks)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Valsartan/Amlodipine, Nifedipine | Hypertension | 564 | Apr 2011actual | 2012-06-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal WomenNCT01224717Measure: Effects of treatment on bone biomarkers. Measure levels of PINP, CTX-1, and serum calcium levels, serum phosphate, P1CP, bone-specific alkaline phosphatase, osteocalcin.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: PTH134, Placebo, Forsteo | Post-menopausal Osteoporosis | 104 | Apr 2011actual | 2011-05-13 |
| Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.NCT01265446results2012-07-26Change From Baseline Sore Throat Pain IntensityRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Lidocaine 8mg + CPC 2mg, Lidocaine 1mg + CPC 2mg | Sore Throat Due to a Common Cold | 250 | Apr 2011actual | 2013-04-24 |
| Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsNCT00806195results2013-07-09Percentages of Subjects With At Least One Severe Systemic Reaction After Any VaccinationRandomized · Open-label · Prevention | Phase 3 | Completed | Biological: MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus | Meningitis, Meningococcal Infection | 7,744 | Mar 2011actual | 2013-07-09 |
| To Evaluate the Safety, Tolerability and Analgesic Efficacy of SAF312 in Postoperative Dental Pain PatientsNCT00986882To evaluate the safety, tolerability, efficacy and dose response of single oral doses of SAF312 in patients with postoperative dental painRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: SAF312A, Placebo, Ibuprofen | Postoperative Pain | 183 | Mar 2011actual | 2020-12-19 |
| Certoparin in Renal Patients Undergoing HemodialysisNCT01179620Number of patients requiring uptitrationOpen-label · Prevention | Phase 3 | Completed | Drug: Certoparin | Renal Dialysis | 109 | Mar 2011actual | 2012-07-10 |
| Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of MigraineNCT01248468results2012-07-30Percent of Subjects Who Are Pain Free at 2 Hours.Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Aspirin, acetaminophen and caffeine, Sumatriptan, Placebo | Pain, Migraine | 752 | Mar 2011actual | 2012-07-30 |
| Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious UveitisNCT01103024Rate of recurrenceRandomized · Triple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Core study in non-infectious active uveitis was terminated | Biological: AIN457, AIN457, AIN457, Placebo | Uveitis | 0 | Feb 2011actual | 2020-09-29 |
| Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive PatientsNCT01042392results2012-04-03Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Aliskiren, Ramipril, Matching placebo to Aliskiren, Matching placebo to Ramipril | Essential Hypertension | 506 | Jan 2011actual | 2012-04-03 |
| A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by MonotherapyNCT01241487Hypertension in patients that will be controlled on each concentration and those that will switch to the higher concentration (160/10)Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: valsartan/amlodipine | Primary Hypertension | 150 | Jan 2011actual | 2017-02-23 |
| Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate CancerNCT00391690• To assess the relationship between change in bone parameters and bone scan with respect to bone metastasesNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Zoledronic acid | Prostate Cancer | 99 | Dec 2010actual | 2016-11-18 |
| Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C PatientsNCT00759200Adverse eventsRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: alb-interferon alfa 2b, alb-interferon alfa 2b, alb-interferon alfa 2b, alb-interferon alfa 2b, peg-interferon | Chronic Hepatitis C | 525 | Dec 2010actual | 2016-11-16 |
| Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseNCT00986414Change from baseline to endpoint in the modified AIMS (Abnormal Involuntary Movement Scale) total scoreRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: AFQ056, AFQ056, AFQ056, AFQ056, AFQ056, Placebo | Parkinson Disease, Dyskinesias | 260 | Dec 2010actual | 2017-02-23 |
| A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus PlaceboNCT01005901results2012-04-12Trough Forced Expiratory Volume in 1 Second (FEV1) at 12 WeeksRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Glycopyrronium bromide, Placebo | Chronic Obstructive Pulmonary Disease | 1,324 | Dec 2010actual | 2012-04-12 |
| Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)NCT00623103results2011-11-28Percentage of Participants With Adverse Events (AEs) Due, or Potentially Due, to Worsening of Parkinson Disease (PD) Motor Symptoms (Tremor, Muscle Rigidity, Bradykinesia, Fall)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Rivastigmine capsule, Rivastigmine transdermal patch | Parkinson's Disease Dementia | 583 | Nov 2010actual | 2011-11-28 |
| Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's PatientsNCT00795418Safety/tolerability of repeated injection of CAD106 at multiple timepoints including but not limited to screening, baseline and through the end of the study (adverse events, physical/neurologic exams, vital signs, 12- lead ECGs, clinical labs, brain MRI)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Biological: Placebo, CAD106 | Alzheimer's Disease | 31 | Nov 2010actual | 2020-12-17 |
| Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for HypertensionNCT00797862results2011-05-17Overall Mean Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Over 8, 16 and 24 WeeksRandomized · Double-masked · Diagnostic | Phase 3 | Completed | Drug: Amlodipine, hydrochlorothiazide, Aliskiren | Hypertension | 1,254 | Nov 2010actual | 2011-10-17 |
| Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic PatientsNCT00900146results2012-02-20Number of Participants With Adverse Events (AEs), Serious Adverse Events, Death and Clinical Significant AEs During 4 Months (Period II)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Terminatedsponsor's stated reason: Numerically modest lowering of HbA1c with canakinumab in combination with metformin was inadequate to continue patients with T2DM into Period IV of this study. | Drug: Canakinumab, Metformin, Placebo | Diabetes Mellitus, Type 2 | 556 | Nov 2010actual | 2012-02-20 |
| Safety of Phenylephrine Hydrochloride, Acetaminophen, Dimethindene Maleate Compared to Phenylephrine Hydrochloride Alone in Healthy VolunteersNCT01026961To compare the effect of phenylephrine hydrochloride 10mg + acetaminophen 500mg + dimethindene maleate 1mg and phenylephrine hydrochloride 10mg alone on vital signsRandomized · Triple-masked | Phase 1/2 | Withdrawnsponsor's stated reason: Study is no longer required by Brazil health authority. | Drug: Phenylephrine HCL, Phenylephrine HCL/Acetaminophen/Dimethindene Maleate | Heart Rate, Blood Pressure, Arrhythmias | 0 | Nov 2010 | 2016-03-03 |
| Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset SeizuresNCT01167335Seizure counts, documenting the percent change in seizure frequency of BGG492 in the maintenance period.Randomized · Quadruple-masked · Treatment | Phase 2 | Withdrawn | Drug: BGG492, Placebo | Partial Onset Seizures | 0 | Nov 2010actual | 2012-05-01 |
| Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)NCT01193907results2012-04-03Number of Subjects Reporting Any Post Immunization ReactionsRandomized · Single-masked · Prevention | Phase 2 | Completed | Biological: NVGH Vi-CRM197 12.5 mcg, NVGH Vi-CRM197 5.0 mcg, NVGH Vi-CRM197 1.25 mcg, Vi-polysaccharide vaccine | Typhoid Fever | 88 | Nov 2010actual | 2014-01-17 |
| Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal InsufficiencyNCT00616811Safety and tolerability in patients with T2DM and severe renal insufficiency over 24 weeks of treatmentRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: vildagliptin, Sitagliptin | Diabetes Mellitus, Type 2 | 148 | Oct 2010actual | 2020-12-17 |
| Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal InsufficiencyNCT00646542To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 24 weeks of treatmentRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Vildagliptin, Placebo | Diabetes Mellitus, Type 2 | 525 | Oct 2010actual | 2020-12-17 |
| Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 DiabetesNCT00821977Measure: To evaluate the efficacy of vildagliptin as monotherapy in patients with T2DM by assessing changes in HbA1c from baseline to 24 weeks.Randomized · Triple-masked · Treatment | Phase 2/3 | Completed | Drug: Vildagliptin, Vildagliptin, Placebo | Diabetes Mellitus, Type 2 | 338 | Oct 2010actual | 2020-12-17 |
| Placebo Versus SBR759 in Lowering Phosphate in Dialysis PatientsNCT01069692Evaluate the change from baseline in 72-hour serum phosphate levels of 4 different doses of SBR759 versus placebo over 4 weeks of treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: SBR759A, SBR759A, SBR759A, SBR759A, SBR759A | Hyperphosphatemia, Chronic Kidney Disease | 115 | Oct 2010actual | 2020-12-19 |
| Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II HypertensionNCT01070030Percentage of participants with stage II hypertension achieving blood pressure (BP) goalNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day) | Stage II Hypertension | 230 | Oct 2010actual | 2017-02-23 |
| Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus AmlodipineNCT01113047Change in mean sitting diastolic blood pressure after 4 weeks of treatmentNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ | Essential Hypertension | 347 | Oct 2010actual | 2013-12-06 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 DiabetesNCT00605475results2012-02-13Mean Change From Baseline in Plasma HbA1c (Glycosylated Hemoglobin / Hemoglobin A1c)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Canakinumab, Placebo, Metformin | Type 2 Diabetes Mellitus | 231 | Sep 2010actual | 2012-02-13 |
| To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan AloneNCT01070043results2011-10-19Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) From Office Blood Pressure MeasurementRandomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Amlodipine 5mg/Valsartan 80 mg, Valsartan | Hypertension, High Blood Pressure | 60 | Sep 2010actual | 2011-10-19 |
| Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy SubjectsNCT01568775Measure: Pharmacokinetics of aliskiren: Area under the concentration-time curve from time zero to 48- hour post-dose (AUC(0-48hrs)), from time zero to the last measurable concentration sampling time (AUClast), from time zero to infinity (AUCinf)Open-label | Phase 1 | Completed | Drug: Aliskiren | End Stage Renal Disease | 12 | Sep 2010actual | 2012-04-02 |
| Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast CancerNCT00332709results2011-11-16Change in Bone Mineral Density (BMD) From Baseline to Month 36Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Letrozole, Zoledronic acid | Osteoporosis, Postmenopausal | 83 | Aug 2010actual | 2011-11-16 |
| Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and CorticosteroidsNCT00658320results2011-09-14Core Study: Number of Patients With Composite Efficacy EndpointRandomized · Open-label · Prevention | Phase 3 | Completed | Drug: Everolimus, Mycophenolate mofetil (MMF), Basiliximab, Cyclosporine A, Corticosteroid | Kidney Transplantation | 122 | Aug 2010actual | 2013-06-21 |
| Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy SurgeryNCT00887861Measure: An efficacy of investigation drug versus Placebo in reducing the seizure rate when administered orally for up to 7days as monotherapy in patients with refractory partial seizures who are undergoing an inpatient evaluation for epilepsyRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Investigational new drug, company code: BGG492, Placebo | Seizures, Epilepsy | 37 | Aug 2010actual | 2017-03-21 |
| Efficacy and Safety of BGG492 in the Treatment of MigraineNCT00892203Reduction in migraine painRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: BGG492, Sumatriptan, Placebo | Migraine | 75 | Aug 2010actual | 2020-12-17 |
| To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes TherapiesNCT01068860results2011-09-05Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-2 Hours, From Baseline to 4 Weeks.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Canakinumab 150 mg, Placebo to Canakinumab | Type 2 Diabetes Mellitus, Impaired Glucose Tolerance | 246 | Aug 2010actual | 2011-09-05 |
| 12-week Efficacy of IndacaterolNCT01072448results2011-08-19Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 12 + 1 Day, Day 85)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Indacaterol 75 μg, Placebo to indacaterol | Chronic Obstructive Pulmonary Disease | 323 | Jul 2010actual | 2011-08-19 |
| Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy PainNCT01089855The decrease of neuropathic pain in diabetic patients using Brief Pain Inventory scale (BPI)Open-label · Treatment | Phase 4 | Completed | Drug: Carbamazepine | Neuropathic Pain | 123 | Jul 2010actual | 2017-07-13 |
| Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment WithdrawalNCT00865020results2011-07-22Change in 24 Hour (24-Hr) Mean Ambulatory Systolic Blood Pressure (MASBP) From the End of the Active Treatment Period to Day 7 of the Withdrawal PeriodRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Aliskiren, Telmisartan, Placebo to Aliskiren, Placebo to Telmisartan | Hypertension | 822 | Jun 2010actual | 2011-07-22 |
| Comparison of Efficacy of Indacaterol Versus Placebo Over 12 WeeksNCT01068600results2011-08-19Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of TreatmentRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Indacaterol, Placebo to indacaterol | Chronic Obstructive Pulmonary Disease | 318 | Jun 2010actual | 2011-08-19 |
| Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)NCT01123941results2012-06-13Number of Subjects Reporting Any Post Immunization ReactionsRandomized · Single-masked · Prevention | Phase 1 | Completed | Biological: Typherix, NVGH Vi-CRM197 | Typhoid Fever | 50 | Jun 2010actual | 2014-01-17 |
| Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT00581945results2011-06-27Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)Randomized · Double-masked · Basic science | Phase 1/2 | Completed | Drug: Canakinumab, Placebo | Chronic Obstructive Pulmonary Disease | 147 | May 2010actual | 2011-06-30 |
| Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential HypertensionNCT01001572results2011-05-24Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 EndpointRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Valsartan/amlodipine 160/5 mg, Valsartan 160 mg, Placebo | Essential Hypertension | 932 | May 2010actual | 2011-05-24 |
| Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic AsthmaNCT00567476results2011-05-23The Mean Change From Baseline to Week 20 in the Overall Asthma Quality of Life Questionnaire (AQLQ)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Omalizumab, Inhaled corticosteroids (ICS), Long-acting beta 2-adrenergic agonist (LABA), Short-acting beta 2-adrenergic agonist (SABA) | Asthma | 116 | Apr 2010actual | 2011-06-30 |
| Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control VaccinesNCT00644059results2014-10-15Number of Subjects (Unprimed) 6 to <36 Months Age With Local and Systemic Reactions After Any Vaccination for All Seasons, Comparison of Adjuvanted Trivalent Influenza Vaccine (aTIV) and Flu Vaccine Control.Randomized · Single-masked · Prevention | Phase 3 | Completed | Biological: Adjuvanted trivalent inactivated subunit influenza vaccine, Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine, Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine | Influenza, Human | 4,902 | Apr 2010actual | 2015-09-18 |
| Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseNCT00685373results2011-05-27The Number of Participants With Adverse Events (AEs), Death, Serious Adverse Events (SAEs), Discontinuation of Study Drug Due to an AE, Infections and Infestations and Injection Site ReactionsOpen-label · Treatment | Phase 3 | Completed | Drug: Canakinumab (ACZ885) | Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease | 166 | Apr 2010actual | 2016-11-04 |
| Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)NCT00426218Safety, tolerability and immunogenicity of subcutaneous (s.c.) ACZ885Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: ACZ885 | Arthritis, Juvenile Rheumatoid | 26 | Mar 2010actual | 2011-08-09 |
| Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular HypertrophyNCT00446563results2011-04-27Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Valsartan, Amlodipine, Hydrochlorothiazide, Losartan | Hypertension; Hypertrophy, Left Ventricular | 90 | Mar 2010actual | 2011-05-11 |
| Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic HypertensionNCT00942994results2011-04-27Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ) | Hypertension | 412 | Mar 2010actual | 2011-06-08 |
| Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)NCT00537082results2011-03-23Number of Patients Free of Gadolinium-enhanced T1-Weighted Magnetic Resonance Imaging (MRI) Lesions at Both Month 3 and Month 6Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: FTY720, Placebo | Multiple Sclerosis | 171 | Feb 2010actual | 2011-04-21 |
| Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.NCT00733863Safety/tolerability assessments at multiple timepoints including but not limited to screening, baseline, and through the end of the study to Week 52.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Biological: Placebo, CAD106 | Alzheimer Disease | 27 | Feb 2010actual | 2020-02-11 |
| Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular DegenerationNCT00504959Safety assessed by incidence and severity of treatment emergent ocular and non-ocular adverse events over 24 month study period with ranibizumab monthly prn (0.5mg/0.05ml)Open-label · Treatment | Phase 4 | Completed | Drug: ranibizumab | Subfoveal Choroidal Neovascularization (CNV), Secondary to Age-related Macular Degeneration (AMD) | 234 | Jan 2010actual | 2016-03-04 |
| A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension StudyNCT00687804results2011-04-19Core Study: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Ranibizumab, Sham to ranibizumab · Procedure: Laser, Sham laser | Diabetic Macular Edema | 345 | Jan 2010actual | 2013-04-01 |
| Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes MellitusNCT00787605results2011-05-23Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Amlodipine, Hydrochlorothiazide (HCTZ), Aliskiren | Hypertension, Diabetes Mellitus | 860 | Jan 2010actual | 2016-10-27 |
| A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of AgeNCT00834041results2011-05-09Maximum Plasma Concentration (Cmax) at Day 1 and Day 8 in 6-11 and 12-17 Year Old PatientsRandomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Aliskiren 3.125 mini-tablets | Hypertension | 39 | Jan 2010actual | 2011-05-09 |
| Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic HypertensionNCT00931710results2011-02-04Change in Mean Sitting Systolic Blood Pressure After 6 WeeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ | Stage 2 Systolic Hypertension | 488 | Jan 2010actual | 2011-03-07 |
| Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of HeartburnNCT01037452results2011-03-28Measure: Number of Participants With no Heartburn (Post Treatment) Following Consumption of Heartburn-inducing MealRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg, Lansoprazole, Calcium carbonate/magnesium hydroxide, Placebo | Heartburn | 120 | Jan 2010actual | 2011-03-28 |
| A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS VaccineNCT01052935Antibody (Ab) response data at 24-months after the last injection given in study V98P1 GMCs, GMRs and associated 95% confidence intervals will also be determinedOpen-label · Prevention | Phase 1 | Completed | Biological: Group B streptococcus (GBS) vaccine | Group B Streptococcus (GBS) Disease | 50 | Jan 2010actual | 2017-06-14 |
| A Long Term Study of Clozapine in Patients With Treatment-resistant SchizophreniaNCT00154258Adverse events during the long term treatment (until NDA approval)Open-label · Treatment | Phase 2 | Completed | Drug: Clozapine | Schizophrenia | 19 | Dec 2009actual | 2020-09-24 |
| A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant SchizophreniaNCT00250575Values of hematological tests during the 24 week treatmentOpen-label · Treatment | Phase 3 | Completed | Drug: Clozapine | Schizophrenia | 43 | Dec 2009actual | 2016-04-21 |
| A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes MellitusNCT00660309results2012-08-29Change From Baseline in Renal Plasma Flow (RPF) After a Single Dose of Aliskiren or IrbesartanRandomized · Open-label | Phase 4 | Completed | Drug: Aliskiren, Irbesartan, Captopril | Type 2 Diabetes Mellitus | 45 | Dec 2009actual | 2012-08-29 |
| Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic HypertensionNCT00797316results2011-01-12Change From Baseline to Week 8 in Mean Sitting Systolic Blood Pressure (msSBP)Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Aliskiren, Hydrochlorothiazide | Hypertension | 532 | Dec 2009actual | 2011-03-11 |
| Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin MonotherapyNCT00822211Change from baseline in HbA1c after 24 weeksRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Vildagliptin 50 mg bid, Vildagliptin 50 mg qd, Placebo | Type 2 Diabetes Mellitus | 404 | Dec 2009actual | 2016-11-18 |
| Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Twice or Three Times Daily in Patients With Acute Ankle SprainNCT00955513results2011-01-26Measure: Pain on Movement on Day 5 (Change From Baseline).Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: diclofenac diethylamine gel 2.32%, diclofenac diethylamine gel 2.32%, Placebo | Grade I/II Ankle Sprain | 242 | Dec 2009actual | 2012-04-20 |
| Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)NCT00145327results2011-04-20Percentage Change in Bone Mineral Density (BMD) of Femoral Neck at Year 6 Relative to Year 3Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Zoledronic Acid, Placebo | Osteoporosis | 2,456 | Nov 2009actual | 2011-06-28 |
| Cardiac T2* in Beta-thalassemia Patients on Deferasirox TreatmentNCT00447694results2021-06-07Magnetic Resonance Imaging (MRI) T2* and Absolute Change From Baseline in MRI T2*Open-label · Treatment | Phase 2 | Completed | Drug: Deferasirox | Beta-thalassemia, Iron Overload | 30 | Nov 2009actual | 2021-06-14 |
| To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes MellitusNCT00550095Change in Albumin Creatinine Ratio (ACR) from baseline over a period of 24 weeks.Open-label · Treatment | Phase 4 | Completed | Drug: valsartan | Microalbuminuria, Proteinuria | 509 | Nov 2009actual | 2017-02-23 |
| Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis BNCT00606099Efficacy at 24 weeks of treatment.Randomized · Open-label · Treatment | Phase 4 | Withdrawnsponsor's stated reason: study was cancelled | Drug: telbivudine, adefovir dipivoxil | Chronic Hepatitis B | 0 | Nov 2009actual | 2012-05-02 |
| A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore SufferersNCT00820534results2011-01-19Clinical Assessment Performed by the Investigator and Skin Temperature at the Cold Sore.Randomized · Double-masked · Prevention | Phase 4 | Completed | Drug: Penciclovir, Placebo | Cold Sore | 126 | Nov 2009actual | 2012-04-20 |
| Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly AdultsNCT00973349results2011-05-25Immunogenicity Results After Each Vaccination by Vaccine Group, in Participants 18 to 64 Years of AgeRandomized · Single-masked · Prevention | Phase 2/3 | Completed | Biological: MF59-eH1N1_f | Influenza | 2,719 | Nov 2009actual | 2015-12-07 |
| Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal NeovascularizationNCT00436553results2011-04-19Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo | Macular Degeneration, Choroidal Neovascularization | 321 | Oct 2009actual | 2011-04-19 |
| Safety, Tolerability, and Efficacy of AEB071 in the Treatment of UveitisNCT00615693Safety and tolerability of AEB071Open-label · Treatment | Phase 2 | Completed | Drug: AEB071 | Uveitis, Posterior Uveitis, Panuveitis | 13 | Oct 2009actual | 2020-12-22 |
| Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute GoutNCT00663169results2013-01-07Percentage of Participants With Improvement in Gout at 72 Hours Post-dose Using a Likert ScaleRandomized · Double-masked · Treatment | Phase 2 | Completed | Biological: canakinumab · Drug: dexamethasone · Other: placebo matching canakinumab, placebo matching dexamethasone | Arthritis, Gouty | 6 | Oct 2009actual | 2013-01-07 |
| Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.NCT00736047Smoking statusRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Biological: NIC002, Placebo | Smokers | 200 | Oct 2009actual | 2017-03-21 |
| Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma PatientsNCT00814216Measure: Change in Forced Expiratory Volume in one second (FEV1) as measured by Spirometry.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: QAV680, Matching placebo for QAV680, Fluticasone Propionate | Asthma | 37 | Oct 2009actual | 2017-03-08 |
| Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During ExerciseNCT00819767results2011-06-28Change in Resting vs. Peak Heart Rate Systolic Blood Pressure (SBP) From Baseline to Week 8 After a Missed DoseRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Aliskiren, Valsartan, Placebo to aliskiren, Placebo to valsartan | Hypertension | 68 | Oct 2009actual | 2011-06-28 |
| A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant HypertensionNCT00817635results2021-06-02Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo | Hypertension | 155 | 2009-10-13actual | 2021-06-02 |
| A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential HypertensionNCT00667719results2021-06-07Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and DeathOpen-label · Treatment | Phase 3 | Completed | Drug: Aliskiren, Amlodipine, Hydrochlorothiazide | Essential Hypertension | 564 | 2009-10-05actual | 2021-06-07 |
| Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)NCT00414609results2011-07-13Core Study: Change From Baseline in Left Ventricular End Systolic Volume (LVESV) as Measured by Echocardiography at End of Study.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Aliskiren, placebo | Myocardial Infarction | 820 | Sep 2009actual | 2012-07-13 |
| Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive DisorderNCT00467402Time to relapse, where relapse is defined by the occurrence of any one of the following:Randomized · Quadruple-masked · Prevention | Phase 3 | Completed | Drug: agomelatine, placebo | Major Depressive Disorder | 644 | Sep 2009actual | 2020-12-23 |
| Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)NCT00568594Safety and tolerability, pharmacokinetics and effects on biomarkers of HDL function of APL180 after a single and 7-daily infusions in healthy volunteers (HV) and in patients with coronary heart disease (CHD)Randomized · Double-masked · Basic science | Phase 1/2 | Completed | Drug: APL180, Placebo | Coronary Heart Disease | 176 | Sep 2009actual | 2020-12-24 |
| A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential HypertensionNCT00631917results2011-06-21Percentage of Participants With Colonic PathologyRandomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: Aliskiren, Ramipril · Other: Placebo to Ramipril, Placebo to Aliskiren | Hypertension | 774 | Sep 2009actual | 2011-07-12 |
| Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis BNCT00646503Proportion of patients experiencing serious adverse events (for all SAEs, and SAEs attributed to study drug). Proportion of patients experiencing adverse events, coded by body system ( all AEs, and AEs attributed to study drug).Open-label · Treatment | Phase 4 | Completed | Drug: Telbivudine | Hepatitis B, Chronic | 150 | Sep 2009actual | 2017-06-22 |
| Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe HypertensionNCT00841672results2011-06-27Mean Sitting Systolic Blood Pressure (msSBP)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Aliskiren/amlodipine 300/10 mg tablet, Amlodipine 10 mg capsule | Moderate to Severe Hypertension | 485 | Sep 2009actual | 2011-07-12 |
| Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant RecipientsNCT00251004results2011-05-10Number of Participants With Composite Efficacy Endpoints - 12 Month AnalysisRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA), Basiliximab, Corticosteroids | Kidney Transplantation, Graft Rejection | 833 | Aug 2009actual | 2011-05-10 |
| Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe HypertensionNCT00765674results2011-05-09Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo, Placebo | Hypertension | 1,191 | Aug 2009actual | 2011-05-09 |
| Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate HypertensionNCT00765947results2011-01-11Percentage of Participants (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped Care, Aliskiren-based RegimenOpen-label · Treatment | Phase 4 | Completed | Drug: Aliskiren, Hydrochlorothiazide, Amlodipine | Essential Hypertension ( Mild to Moderate) | 256 | Aug 2009actual | 2020-08-06 |
| Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout PatientsNCT00798369results2011-05-16The Dose of Canakinumab for Treatment of Acute Flares in Gout Patients That Leads to the Same Efficacy as Triamcinolone Acetonide With Respect to Pain Intensity on a 0-100 mm Visual Analog Scale (VAS)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Canakinumab, Canakinumab, Canakinumab, Canakinumab, Canakinumab, Triamcinolone acetonide | Acute Gout | 200 | Aug 2009actual | 2012-04-10 |
| Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 HypertensionNCT00853957results2011-01-21Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Aliskiren/Amlodipine, Amlodipine | Hypertension | 443 | Aug 2009actual | 2012-04-30 |
| Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate HypertensionNCT00867490results2011-02-01Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the StudyNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Candesartan+HCTZ - Phase 1, Aliskiren+HCTZ - Phase 2, Aliskiren+HCTZ+amlodipine - Phase 3 | Hypertension | 186 | Aug 2009actual | 2011-05-06 |
| Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease PatientsNCT00888004Number and severity of Dyskinesias and the safety and tolerability of administering AFQ056 in combination with L-dopaRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: AFQ056, Placebo | Parkinson's Disease, L-dopa Induced Dyskinesia | 28 | Aug 2009actual | 2016-04-19 |
| Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid ArthritisNCT00554606results2021-07-09Number of Participants With Adverse Events and Serious Adverse EventsOpen-label · Treatment | Phase 2 | Completed | Drug: Canakinumab | Rheumatoid Arthritis | 115 | 2009-08-13actual | 2021-07-09 |
| A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With HypertensionNCT00817414results2021-06-02Maximum Tolerated Dose (MTD) of LCI699 With Respect to Effect on the Adrenocorticotropic Hormone (ACTH)-Stimulated Cortisol Response Following ACTH Stimulation in Hypertensive ParticipantsRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: LCI699-matching placebo, LCI699 | Hypertension | 63 | 2009-08-12actual | 2021-06-02 |
| Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisNCT00289978results2011-03-16Estimated Annualized Aggregate Relapse Rate (ARR)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Fingolimod 1.25 mg, Fingolimod 0.5 mg, Placebo | Relapsing-remitting Multiple Sclerosis | 1,272 | Jul 2009actual | 2012-04-11 |
| Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)NCT00433017results2011-02-04Change From Baseline in Best-corrected Visual Acuity (BCVA) at Month 12.Randomized · Quadruple-masked · Treatment | Phase 2/3 | Terminatedsponsor's stated reason: Study was terminated based on the results of analyses performed as planned at Month 12. | Drug: Verteporfin Photodynamic Therapy, Ranibizumab, Placebo | Macular Degeneration, Choroidal Neovascularization | 255 | Jul 2009actual | 2011-04-21 |
| Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic SyndromeNCT00542269results2011-05-24Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study - Aliskiren/Ramipril/Amlodipine vs Ramipril/Amlodipine)Randomized · Triple-masked · Treatment | Phase 4 | Terminatedsponsor's stated reason: Early termination of the study due to slow recruitment. | Drug: Amlodipine, Aliskiren, Ramipril | Hypertension With Metabolic Syndrome | 178 | Jul 2009actual | 2011-05-24 |
| Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C PatientsNCT00724776Safety and tolerability after single doseOpen-label · Treatment | Phase 1 | Completed | Biological: Albinterferon alfa 2b | Chronic Hepatitis C | 30 | Jul 2009actual | 2020-12-08 |
| 8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 HypertensionNCT00809926results2011-05-02Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Valsartan/aliskiren, Valsartan | Stage 2 Hypertension | 451 | Jul 2009actual | 2011-05-02 |
| Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly SubjectsNCT00956449Immunogenicity and tolerability of the Flu vaccines is being measuredNon-randomized · Open-label · Prevention | Phase 2 | Completed | Biological: Seasonal Influenza Vaccine | Influenza, Seasonal Influenza | 126 | Jul 2009actual | 2017-03-28 |
| Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant PatientsNCT00419926results2011-01-11Number of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and DeathRandomized · Open-label · Prevention | Phase 4 | Completed | Drug: Enteric-coated mycophenolate sodium (Myfortic), Cyclosporine (Neoral), Prednisone | Kidney Transplantation | 313 | Jun 2009actual | 2011-03-01 |
| A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical PatientsNCT00451412Incidence of venous thromboembolism during treatment (proximal deep vein thrombosis, pulmonary embolism, death related to venous thromboembolism)Randomized · Triple-masked · Prevention | Phase 3 | Completed | Drug: Certoparin, Unfractionated Heparin | Thromboembolism | 3,254 | Jun 2009actual | 2012-07-25 |
| Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine AloneNCT00778921results2011-03-23Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of StudyRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Amlodipine 10 mg, Aliskiren 150, Amlodipine 300 | Hypertension | 847 | Jun 2009actual | 2016-10-27 |
| Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010NCT00945841Evaluation of antibody response to each influenza vaccine antigen, as measured by haemagglutination inhibition (HI) test on Day 0 and on Day 21Randomized · Open-label · Prevention | Phase 3 | Completed | Biological: inactivated split influenza vaccine | Seasonal Influenza | 126 | Jun 2009actual | 2017-04-07 |
| Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010NCT00956761results2016-01-27Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One Vaccination of FLUADOpen-label · Prevention | Phase 2 | Completed | Biological: Seasonal Influenza Vaccine (MF59C.1) | Seasonal Influenza | 63 | Jun 2009actual | 2016-01-27 |
| Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the KneeNCT00477217Changes from baseline after 3 months in a) knee pain scores (using the KOOS pain subscale), and b) volume of osteonecrotic lesion (indicated by bone marrow oedema) on MRI.Randomized · Open-label · Treatment | Phase 2 | Withdrawn | Drug: Zoledronic acid | Osteonecrosis | 0 | May 2009actual | 2016-09-23 |
| Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid ArthritisNCT00505089- Pharmacokinetic/total IL-1beta pharmacodynamic relationship in joint fluids of patients with rheumatoid arthritis treated with different doses of ACZ885 - Impact of the subcutaneous versus intravenous administrationRandomized · Open-label · Treatment | Phase 1/2 | Terminated | Drug: ACZ885, ACZ885, ACZ885, ACZ885 | Rheumatoid Arthritis | 11 | May 2009actual | 2009-08-25 |
| Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing OffNCT00642356results2011-01-11Change From Baseline on the Non-motor Score of the Quantitative Wearing-Off Questionnaire 9 Item (QWOQ-9)Randomized · Quadruple-masked · Treatment | Phase 4 | Terminatedsponsor's stated reason: slow enrollment | Drug: Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa | Parkinson's Disease | 14 | May 2009actual | 2011-02-18 |
| Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy SubjectsNCT00651105GLP-1 and non GLP-1 effects of LAF237 on glucagon secretion in patients with Type-2 diabetes and matching healthy subjectsRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Vildagliptin, Placebo | Type-2 Diabetes, Healthy | 63 | May 2009actual | 2016-11-18 |
| Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal VasculopathyNCT00674323results2011-01-25Number of Participants With Complete Regression (CR) of Polyps Measured by Indocyanine Green Angiography (ICGA)Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Verteporfin Photodynamic Therapy, Ranibizumab | Polypoidal Choroidal Vasculopathy | 61 | May 2009actual | 2011-04-19 |
| Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary HyperaldosteronismNCT00732771Systolic blood pressure over a 7-week forced titration treatment periodNon-randomized · Single-masked · Treatment | Phase 2 | Completed | Drug: LCI699 | Primary Hyperaldosteronism | 12 | May 2009actual | 2009-08-26 |
| Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren AloneNCT00777946results2011-06-15Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Aliskiren 300 mg, Aliskiren/Amlodipine 300/5 mg, Aliskiren/Amlodipine 300/10 mg, Placebo to Aliskiren, Placebo to Aliskiren/Amlodipine | Hypertension | 818 | May 2009actual | 2011-07-12 |
| A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of AgeNCT00848887Assessment of all adverse events from time of vaccination through study end will be collected to for safety assessment.Randomized · Single-masked · Prevention | Phase 1 | Completed | Biological: Adjuvanted and un-adjuvanted influenza vaccines | Influenza | 410 | May 2009actual | 2014-01-24 |
| A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00856193results2011-05-06Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-24 Hours on Day 14Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Placebo, NVA237 | Chronic Obstructive Pulmonary Disease | 33 | May 2009actual | 2016-09-14 |
| Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary SyndromeNCT00409578results2011-02-02Change From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 8Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg | Post Acute Coronary Syndrome, Myocardial Ischemia | 1,101 | Apr 2009actual | 2011-04-19 |
| Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic UrticariaNCT00481676results2011-10-21Change in the Weekly Urticaria Activity Score (UAS7) From Baseline to the End of the Study (Week 24)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Omalizumab 75-375 mg, Placebo to omalizumab, Loratadine, Clemastine | Chronic Urticaria | 49 | Apr 2009actual | 2011-10-21 |
| Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's DiseaseNCT00549601results2011-03-24Percentage of Patients Who Had a Gastrointestinal Adverse Event (AE) at Any Time During the StudyRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day), Rivastigmine patch (9.5 mg/day), Rivastigmine capsules (6 mg to 12 mg/day) | Alzheimer's Disease | 142 | Apr 2009actual | 2011-03-24 |
| Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using OctreotideNCT00584298- 5 sensory pressure thresholds [mmHg] from ascending method of limits (AML) barostat protocol. - 16 sensory intensity ratings from the random phasic distention (RPD) barostat protocol.Randomized · Double-masked | Phase 1 | Completed | Drug: SMS995, Placebo | Irritable Bowel Syndrome (IBS) | 50 | Apr 2009actual | 2009-05-08 |
| Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II HypertensionNCT00705575results2011-01-21Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 12)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg), Aliskiren (300 mg) | Hypertension | 688 | Apr 2009actual | 2011-05-30 |
| Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled StudyNCT00706134results2011-06-17Change in Mean Sitting Systolic Blood Pressure (msSBP)From Baseline to End of Study (Week 8)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Placebo, Aliskiren 75 mg, Aliskiren 150 mg, Aliskiren 300 mg | Hypertension | 756 | Apr 2009actual | 2011-06-28 |
| Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent AsthmaNCT00746330results2011-04-14The Standardized Forced Expiratory Volume in 1 Second (FEV1) Using Area Under the Curve (AUC) From 0 to 12 Hours (0-12h) Post-dose by TreatmentRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF | Asthma | 32 | Apr 2009actual | 2011-06-07 |
| Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older PopulationNCT00760266results2011-01-21Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 4Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Aliskiren, Hydrochlorothiazide | Hypertension | 451 | Apr 2009actual | 2011-04-04 |
| Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly SubjectsNCT00841763results2013-01-18Number of Subjects With at Least One Reactogenicity Sign After Two Doses of the Adjuvanted Pandemic Influenza Vaccine.Randomized · Double-masked · Prevention | Phase 3 | Completed | Biological: Placebo (PL), Trivalent influenza virus vaccine (TIV), Adjuvanted monovalent influenza virus vaccine (aH5N1), Adjuvanted trivalent influenza virus vaccine (aTIV) | Pandemic Influenza Disease | 3,647 | Apr 2009actual | 2021-04-23 |
| Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative SteroidsNCT00149890results2011-09-22Number of Participants With at Least One Biopsy Proven Acute Rejection (BPAR) Episode, Graft Loss or Death Within the First Three Months Post-transplantationRandomized · Open-label · Prevention | Phase 3 | Completed | Drug: Basiliximab, Cyclosporine/cyclosporine microemulsion, Steroid | Liver Transplantation, Infection | 77 | Mar 2009actual | 2011-09-22 |
| Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant RecipientsNCT00413920results2011-02-07Number of Participants With the Occurrence of Treatment Failures at 6 Months Post-transplantationRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Enteric-coated mycophenolate sodium (EC-MPS), Prednisone | Renal Transplantation | 222 | Mar 2009actual | 2011-04-21 |
| Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black PatientsNCT00477334results2011-03-16Investigator Assessed Time to Healing of All Non-aborted Genital Herpes LesionsRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Famciclovir, Placebo | Genital Herpes | 463 | Mar 2009actual | 2011-03-28 |
| Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)NCT00677807results2011-08-18The Number of Participants With a Clinically Notable Pulse Rate During 52 Weeks of Treatment With Indacaterol 150 µg or 300 µg Compared to PlaceboRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Indacaterol, Placebo | COPD | 415 | Mar 2009actual | 2011-08-22 |
| Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 HypertensionNCT00772577results2011-03-02Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Aliskiren Hydrochlorothiazide, Ramipril | Hypertension | 386 | Mar 2009actual | 2011-03-11 |
| Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)NCT00412750results2011-07-13Percentage of Participants Who Achieved HBV DNA Non-detectability With Peginterferon Alpha-2a Plus Telbivudine Combination Therapy Versus Peginterferon Alpha-2a MonotherapyRandomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Enrollment stopped for safety issues | Drug: Telbivudine (LdT), peginterferon alpha-2a | Hepatitis B | 159 | Feb 2009actual | 2011-07-13 |
| Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With OsteoporosisNCT00439244results2011-04-20Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Zoledronic acid, Placebo, Teriparatide | Osteoporosis | 412 | Feb 2009actual | 2011-04-20 |
| Pharmacokinetic Study of AEB071 in Patients Following Liver TransplantationNCT00545259-Pharmacokinetic of AEB071 & its primary metabolite, AEE800 at predose & up to 72 hours post-operatively -Safety & tolerability (vital signs,ECGs,clinical lab evaluations,seroius/adverse events) -AEB071,AEE800 & tacrolimus in blood for both PeriodsNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: AEB071 | de Novo Liver Transplantation | 13 | Feb 2009actual | 2020-12-08 |
| Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled TobramycinNCT00634192To evaluate the serum pharmacokinetics (PK) of inhaled tobramycin (AUC 0-90') of continuous daily dosing regimens with 2x300mg/d Tobramycin Nebuliser Solution (=TNS) inhaled with the PARI eFlow® rapid in Cystic Fibrosis (CF) subjectsOpen-label · Treatment | Phase 3 | Completed | Drug: tobramycin, tobramycin | Pseudomonas Infections | 50 | Feb 2009actual | 2017-02-24 |
| Efficacy, Safety and Tolerability of AFQ056 in Fragile X PatientsNCT00718341Aberrant-Behavior Checklist- Community EditionRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: AF056, Placebo | Fragile X Syndrome | 30 | Feb 2009actual | 2020-02-11 |
| A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate AsthmaNCT00785083Change from baseline in Pulmonary function tests (particularly Forced Expiratory Volume at 1 sec (FEV1) at Day 10Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: FTY720, Placebo | Asthma | 36 | Feb 2009actual | 2016-11-18 |
| Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail OnychomycosisNCT00459537results2011-04-20Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 WeeksRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: terbinafine hydrogen chloride, amorolfine nail lacquer | Onychomycosis | 1,029 | Jan 2009actual | 2011-05-06 |
| Pharmacokinetic Study of Vildagliptin in Patients With Renal ImpairmentNCT00567047• Pharmacokinetic measuresOpen-label · Treatment | Phase 1 | Completed | Drug: vildagliptin | Type-2 Diabetes | 96 | Jan 2009actual | 2009-03-25 |
| Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active ControlNCT00567996results2011-08-18Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of TreatmentRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Indacaterol 150 μg, Salmeterol 50 μg, Placebo to Indacaterol, Placebo to Salmeterol | Chronic Obstructive Pulmonary Disease (COPD) | 1,002 | Jan 2009actual | 2011-08-18 |
| The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT00620022results2011-08-17Exercise Duration Time Assessed by Constant-load Cycle Ergometry at the End of Each Treatment PeriodRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Indacaterol 300 μg, Placebo | Chronic Obstructive Pulmonary Disease | 90 | Jan 2009actual | 2011-08-17 |
| A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)NCT00622713results2011-07-26Percentage of Patients Who Achieved and Maintained the Maximum Dose of 10 cm^2 Rivastigmine Patch for at Least 8 Weeks During 24 Weeks StudyOpen-label · Treatment | Phase 4 | Completed | Drug: Rivastigmine transdermal patch | Alzheimer's Disease | 228 | Jan 2009actual | 2011-07-26 |
| A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE LevelsNCT00624832results2011-02-14Early Phase Allergic Response After Treatment With Study Drug in Active and Placebo PatientsRandomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Xolair, Placebo | Asthma | 60 | Jan 2009actual | 2011-04-19 |
| The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) MonotherapyNCT00666536results2010-12-10Change From Baseline to Week 4 in Mean Sitting Systolic Blood Pressure (MSSBP)Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: valsartan and amlodipine, valsartan and amlodipine | Hypertension | 728 | Jan 2009actual | 2016-10-27 |
| Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and SteroidsNCT00284947to describe the pharmacokinetics of basiliximab over the 6-month study course and to determine whether serum concentrations remain above CD25 receptor saturation levelsOpen-label · Prevention | Phase 4 | Completed | Drug: basiliximab, MMF/EC-MPS, Corticosteroids | Kidney Transplantation, Adverse Effects | 7 | Dec 2008actual | 2017-03-29 |
| A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant RecipientsNCT00369161results2011-01-19Renal Function Assessed by Calculated Glomerular Filtration Rate (cGFR)Randomized · Open-label · Prevention | Phase 4 | Completed | Drug: Everolimus (RAD001), Tacrolimus, Basiliximab, Corticosteroids | Renal Transplantation | 228 | Dec 2008actual | 2017-03-03 |
| Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With OsteoporosisNCT00404820results2011-07-01Change of Cross-linked N-telopeptide of Type I Collagen (NTx) Level Assessed as Standardized Area Under the Curve From Screening to Month 12 in the Intent-to-Treat PopulationRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Zoledronic acid 5 mg solution, Alendronate 70 mg tablets, Calcium/Vitamin D | Osteoporosis | 604 | Dec 2008actual | 2011-07-01 |
| Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult SubjectsNCT00481065results2013-02-28Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza VaccineRandomized · Open-label · Prevention | Phase 2 | Completed | Biological: MF59-eH5N1, eTIV_a, MF59-eH5N1 + eTIV_a | Pandemic, Avian Influenza | 405 | Dec 2008actual | 2014-02-03 |
| Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid ArthritisNCT00487825results2011-05-06Response to Intravenous Canakinumab and Oral Methotrexate (MTX) Compared to MTX Alone as Determined by 50% Improvement in Symptoms According to the American College of Rheumatology Criteria (ACR50)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Canakinumab (investigational), Placebo, Methotrexate (MTX) | Rheumatoid Arthritis | 78 | Dec 2008actual | 2012-08-01 |
| Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic AsthmaNCT00598104- Forced expiratory volume in 1 second (FEV1)at baseline and until study completion - Levels of eosinophils in sputumRandomized · Double-masked · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Due to the lack of enrolment and complexity of design, this study in asthma was terminated. No subjects have been dosed for this study. | Drug: QAX576, Placebo | Asthma | 0 | Dec 2008actual | 2016-03-04 |
| A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active ControlNCT00615459results2011-08-1724-hour Post-dose Trough Forced Expiratory Volume in 1 Second (FEV1) After 14 Days of TreatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Indacaterol, Tiotropium, Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 169 | Dec 2008actual | 2011-08-17 |
| Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 DiabetesNCT00633997Skin concentration of vildagliptin and its two metabolites, LAY151 and LAF237-O-Glucuronide, compared to the plasma concentration on Day 10Non-randomized · Open-label · Basic science | Phase 1/2 | Terminatedsponsor's stated reason: After analysis of the existing data, it was determined that additional skin biopsy samples would not be required to determine study outcome. | Drug: Vildagliptin, Vildagliptin | Diabetes Mellitus, Type 2 | 22 | Dec 2008actual | 2020-12-17 |
| Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal TransplantNCT00646737Gastrointestinal symptoms in renal transplant patients treated with the immunosuppression regimen of tacrolimus and mycophenolate at baseline, 8 and 16 weeksOpen-label · Treatment | Phase 4 | Completed | Drug: Mycophenolate sodium | Kidney Transplantation | 18 | Dec 2008actual | 2017-02-23 |
| A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure ChamberNCT00784732Total Nasal Symptom Score (TNSS) over the last 2 hours of exposure in the EEC Percentage nasal lavage eosinophil count post EECRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: QAV680, QAV680, Mometasone Furoate | Seasonal Allergic Rhinitis | 44 | Dec 2008actual | 2016-11-18 |
| Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory FunctionNCT00444106results2011-03-16Percentage of Participants With Auditory Abnormalities at Day 7 Assessed by Auditory Brainstem Response (ABR) Wave III Latency Changes on Day 7(a Type of Hearing Test)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Artesunate-mefloquine, Atovaquone-proguanil, Artemether-lumefantrine | Malaria, Falciparum | 265 | Nov 2008actual | 2011-04-05 |
| Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex InfectionNCT00448227results2010-12-14Pharmacokinetics of Single Dose - TmaxNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: famciclovir | Herpes Simplex | 18 | Nov 2008actual | 2011-02-11 |
| EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)NCT00470678Mean change in best-corrected visual acuity (BCVA) from Baseline, Month 4 and Month 12 as assessed with ETDRS (Early Treatment for Diabetic Retinopathy Study)-like charts at a distance of four metersOpen-label · Treatment | Phase 3 | Completed | Drug: ranibizumab | Choroidal Neovascularization, Age-Related Macular Degeneration | 95 | Nov 2008actual | 2016-11-18 |
| Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's DiseaseNCT00561392results2011-03-11Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Who Completed the StudyNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Rivastigmine 5 and 10 cm^2 patch | Alzheimer's Disease | 208 | Nov 2008actual | 2012-04-16 |
| Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.NCT00654875results2011-06-15Change From Baseline to Week 6 in the Mean 24-hour Ambulatory Diastolic Blood Pressure (MADBP)Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Aliskiren, Placebo to Aliskiren | Essential Hypertension | 328 | Nov 2008actual | 2011-06-28 |
| Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)NCT00446524Safety assessed by serious and non-serious adverse eventsRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Valsartan + Amlodipine besilate | Hypertension | 403 | Oct 2008actual | 2017-03-28 |
| Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells SyndromeNCT00465985results2011-02-11Percent of Participants With Disease Flare in Part II (After 24 Weeks of the Double-blind Part)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: ACZ885, Placebo | Muckle Wells Syndrome | 35 | Oct 2008actual | 2017-08-28 |
| Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy SubjectsNCT00703703Mean heart rate per 24 hours following exposure to darifenacin 15 mg o.d. and tolterodine ER 4 mg o.d., at baseline and Day 7Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Darifenacin, Tolterodine, Placebo | Healthy | 117 | Oct 2008actual | 2012-08-02 |
| Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant PatientsNCT00154310results2011-05-24Renal Function (Nankivell Formula) at Month 12 Post Transplantation.Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Everolimus, Cyclosporine, Enteric-coated mycophenolate sodium, Corticosteroids | Renal Transplantation | 300 | Sep 2008actual | 2013-11-13 |
| Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic AsthmaNCT00264849results2011-07-25Persistency of Response and Non-response as Based on Investigator's Global Evaluation of Treatment Effectiveness (GETE)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Omalizumab · Other: Optimized asthma therapy | Asthma | 406 | Sep 2008actual | 2018-06-29 |
| Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate MofetilNCT00400647To determine the effect of the use of EC-MPS on the quality of life of patients requiring MMF dose reduction due to gastrointestinal symptomsRandomized · Open-label · Prevention | Phase 4 | Completed | Drug: Enteric-coated Mycophenolate sodium (EC-MPS), Mycophenolate mofetil | Maintenance Kidney Transplant | 136 | Sep 2008actual | 2017-02-07 |
| Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid ArthritisNCT00424346results2013-06-19Percentage of American College of Rheumatology [ACR] 50 Criteria Responders at Week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Canakinumab, Placebo | Rheumatoid Arthritis | 274 | Sep 2008actual | 2014-02-10 |
| Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial ObstructionNCT00460577results2011-04-19Mean Change in Maximum Expiratory Flow From Baseline to Final EvaluationRandomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: Formoterol fumerate, fenoterol/ipratropium bromide | Acute Bronchial Obstruction, Asthma | 60 | Sep 2008actual | 2011-04-19 |
| Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.NCT00500539results2011-04-27The Number of Participants With Confirmed Positive Human Antihuman Antibody (HAHA) Results at the End of the 16-week Follow-up PeriodNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: omalizumab | Asthma | 155 | Sep 2008actual | 2011-06-02 |
| Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid ArthritisNCT00504595results2011-06-23Response to Treatment (ACR20) in Adult Patients With Established Rheumatoid Arthritis (RA)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: ACZ885 (investigational), Placebo | Rheumatoid Arthritis | 80 | Sep 2008actual | 2012-08-07 |
| Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent AsthmaNCT00624702Presence of cough within 5 minutes post dose and the onset of cough (relative to inhalation)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Indacaterol maleate, Indacaterol maleate, Indacaterol maleate, Placebo | Asthma | 98 | Sep 2008actual | 2020-12-19 |
| Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)NCT00290771results2011-05-16Percentage of Patients With an Objective Overall Response (OOR)Non-randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Lack of efficacy | Drug: Imatinib tablets, Hydroxyurea capsules | Recurrent Glioblastoma Multiforme (GBM) | 231 | Aug 2008actual | 2011-05-16 |
| Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir AloneNCT00376259results2011-05-17The Proportion of Participants Who Experienced Virologic BreakthroughRandomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: The study was not completed as planned and was terminated early with agreement from the European Medicines Agency (EMEA) | Drug: telbivudine, adefovir dipivoxil | Hepatitis B | 43 | Aug 2008actual | 2011-06-30 |
| 26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00463567results2011-08-18Trough Forced Expiratory Volume in 1 Second (FEV1) Assessed by Spirometry 24 Hour Post Dose After 12 Weeks of TreatmentRandomized · Quadruple-masked · Treatment | Phase 2/3 | Completed | Drug: Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol | Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive | 2,059 | Aug 2008actual | 2011-08-18 |
| Safety and Tolerability of Omalizumab in Patients With Mild to Moderate AsthmaNCT00546143Safety and tolerability of omalizumab assessed by AEs and SAEsNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Omalizumab, Omalizumab, Omalizumab | Asthma | 32 | Aug 2008actual | 2010-09-02 |
| An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated HayfeverNCT00584584Markers of allergic inflammation in the nose measured over 5-8 days post-dose.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: QAX576, Placebo | Allergic Rhinitis | 36 | Aug 2008actual | 2017-02-24 |
| An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)NCT00636961results2011-08-30Inspiratory Capacity (IC) at Peak Time and at Isotime on Day 14Randomized · Quadruple-masked · Supportive care | Phase 2 | Completed | Drug: Indacaterol 300μg, Placebo | Chronic Obstructive Pulmonary Disease | 27 | Aug 2008actual | 2011-08-30 |
| Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT00669617results2011-08-17Forced Expiratory Volume in 1 Second (FEV1) at 5 Minutes Post-doseRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol | Chronic Obstructive Pulmonary Disease | 89 | Aug 2008actual | 2011-09-12 |
| Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal SubjectsNCT00676312•Safety and tolerability of ascending single doses of PTH134 over 24 hours as compared to baseline. •Pharmacokinetics after ascending single doses of PTH134, including comparison with reference drug Forteo 20 µg sc over 24 hours.Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: PTH134 | Postmenopausal Osteoporosis | 32 | Aug 2008actual | 2008-12-11 |
| Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects.NCT00731523PK profile comparison between healthy volunteers and severe renal impaired patients, 3 weeksOpen-label · Other | Phase 1 | Completed | Drug: fingolimod (FTY720) | Renal Insufficiency | 18 | Aug 2008actual | 2020-12-09 |
| Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant PatientsNCT00154284results2011-03-11Renal Function Measured by Calculated Glomerular Filtration Rate (GFR Calculated According to the Nankivell Formula)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Everolimus (Certican), Cyclosporine (Neoral), Steroid, Basiliximab (Simulect) | Organ Transplantation, Renal Transplantation | 114 | Jul 2008actual | 2018-08-09 |
| A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.NCT00386607results2011-05-10Overall Percentage of Patients With Adverse EventsNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Aliskiren, Valsartan, Hydrochlorothiazide (HCTZ) | Hypertension | 601 | Jul 2008actual | 2014-02-10 |
| Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active ControlNCT00393458results2011-08-18Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 + 1 Day, Day 85Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Indacaterol, Formoterol, Placebo to indacaterol, Placebo to formoterol | Chronic Obstructive Pulmonary Disease | 1,732 | Jul 2008actual | 2011-08-18 |
| Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral DensityNCT00431444results2011-03-11Change From Baseline in Urine N-telopeptide of Type 1 Collagen (NTx.)Randomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: Raloxifene, Zoledronic acid, Placebo oral pills, Placebo intravenous (i.v.) infusion | Osteoporosis | 110 | Jul 2008actual | 2011-03-29 |
| Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With MetforminNCT00494884Change from baseline in HbA1cRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: vildagliptin | Diabetes Mellitus, Type 2 | — | Jul 2008actual | 2017-02-27 |
| Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mgNCT00529451results2011-03-25Non-inferiority of Aliskiren 300 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Aliskiren, Ramipril | Hypertension | 1,613 | Jul 2008actual | 2011-03-25 |
| Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)NCT00558285results2012-11-22Change From Baseline in Mean 24 Hour Heart Rate at Day 14Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: indacaterol/glycopyrrolate, indacaterol, glycopyrrolate, placebo | Chronic Obstructive Pulmonary Disease (COPD) | 257 | Jul 2008actual | 2012-11-30 |
| Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00615030results2011-08-17Trough Forced Expiratory Volume in 1 Second (FEV1) Following 14 Days of Evening Dosing of Indacaterol Versus PlaceboRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Indacaterol, Salmeterol, Placebo to Indacaterol, Placebo to Salmeterol | Chronic Obstructive Pulmonary Disease (COPD) | 96 | Jul 2008actual | 2011-08-17 |
| Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00624286results2011-08-18Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 12 + 1 Day, Day 85)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Indacaterol 150 μg, Placebo to indacaterol | Chronic Obstructive Pulmonary Disease | 416 | Jul 2008actual | 2011-08-18 |
| Evaluation of HIV-1, HCV and HBV Blood Screening Tests With Human Blood Donor SpecimensNCT00552214Sensitivity and SpecificityOpen-label · Prevention | Not applicable | Completed | Device: Blood test | Screening for the Presence of HIV-1, RNA and HBV DNA in Blood Donations | 10,290 | 2008-07-01actual | 2021-02-21 |
| Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center InvolvementNCT00284050results2011-01-20Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Ranibizumab 0.3 mg, Ranibizumab 0.5 mg, Sham injection | Diabetic Macular Edema | 151 | Jun 2008actual | 2011-02-24 |
| Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant RecipientsNCT00284934results2011-05-02Renal Function Assessed by Change in Estimated Glomerular Filtration Rate(eGFR)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Enteric-coated mycophenolate sodium (EC-MPS), Tacrolimus, Corticosteroids | Kidney Diseases | 94 | Jun 2008actual | 2011-05-02 |
| Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-offNCT00391898results2011-03-15Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living [ADL]) Score From Baseline to Month 3Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Levodopa/carbidopa/entacapone, Levodopa/carbidopa | Parkinson's Disease | 95 | Jun 2008actual | 2011-03-15 |
| A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)NCT00463242Change from Baseline to Week 8 on the total score Hamilton Depression Rating ScaleRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Agomelatine, paroxetine, placebo | Major Depressive Disorder | 501 | Jun 2008actual | 2020-12-23 |
| A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid TumorsNCT00487058Safety and tolerability assessed by Adverse Events Characterization of the pharmacokinetic profile of gimatecan Anti-tumor activity assessed by Response Evaluation Criteria in Solid Tumors RECIST)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Gimatecan | Advanced Solid Tumors | 28 | Jun 2008actual | 2009-11-19 |
| Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and SalmeterolNCT00531050results2012-05-23Percentage of Participants With Maximum Heart Rate Increase During Exercise in Part 1 of the StudyRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Indacaterol, Placebo, Salmeterol | Chronic Obstructive Pulmonary Disease | 27 | Jun 2008actual | 2012-05-23 |
| Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a SubgroupNCT00579345results2011-10-10Number of Randomized Participants Reporting Local and Systemic Reactions.Randomized · Single-masked · Prevention | Phase 3 | Completed | Biological: Cell culture derived seasonal trivalent influenza vaccine (cTIV), Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)., cTIV or eTIV_a, cTIV+PV OR eTIV_a+PV | Influenza | 1,522 | Jun 2008actual | 2017-01-27 |
| A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus MetforminNCT00468039glycosylated hemoglobin (HbA1c)at Baseline and week 24Open-label · Treatment | Phase 3 | Completed | Drug: vildagliptin + metformin | Diabetes Mellitus, Type 2 | 94 | 2008-06-06actual | 2020-12-19 |
| LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell LymphomaNCT00412997To determine the maximum-tolerated dose of LBH589Open-label · Treatment | Phase 1 | Completed | Drug: LBH589 | Tumors, Cutaneous T-Cell Lymphoma | 14 | May 2008actual | 2012-11-27 |
| A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00557466results2013-01-18The Mean Change From Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: indacaterol, formoterol, placebo to indacaterol, placebo to formoterol, short acting β2- agonist | COPD | 568 | May 2008actual | 2013-01-18 |
| Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopaNCT00582673Number and severity of Dyskinesias and the safety and tolerability of administering AFQ056 in combination with L-dopaRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: AFQ056, Placebo | Parkinson's Disease | 31 | May 2008actual | 2010-05-14 |
| SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular DegenerationNCT00331864results2011-01-04Percentage of Patients With Ocular Adverse Events (AEs) in the Study EyeNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Ranibizumab | Age Related Macular Degeneration, Choroidal Neovascularization | 531 | Apr 2008actual | 2011-02-18 |
| An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood PressureNCT00402103results2011-01-11Overall Percentage of Patients With Adverse EventsNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Aliskiren, Amlodipine, Hydrochlorothiazide | Hypertension | 556 | Apr 2008actual | 2011-03-10 |
| Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone MetastasesNCT00434317Measurement of pain assessed by a Visual Analogue Scale (VAS)Open-label · Treatment | Phase 4 | Completed | Drug: Zoledronic acid | Neoplasm Metastasis | 80 | Apr 2008actual | 2017-02-23 |
| Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt NephropathyNCT00464776Investigate the antiproteinuric effect of increasing doses of Aliskiren compared to matching placebo.Randomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: Aliskiren, Aliskiren, Aliskiren, Aliskiren | Diabetes Mellitus, Type 2 | 26 | Apr 2008actual | 2011-02-04 |
| Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With AsthmaNCT00556673results2013-04-22Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: indacaterol maleate/mometasone furoate, placebo to indacaterol maleate/mometasone furoate, fluticasone proprionate / salmeterol xinafoate | Asthma | 31 | Apr 2008actual | 2013-04-22 |
| Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent AsthmaNCT00557440results2013-03-21Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: fluticasone propionate/salmeterol, indacaterol maleate / mometasone furoate, placebo to indacaterol/mometasone, placebo to fluticasone propionate/salmeterol | Asthma | 37 | Apr 2008actual | 2013-03-21 |
| Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate AsthmaNCT00605306results2013-04-22Participants With Adverse EventsRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: indacaterol maleate / mometasone furoate, placebo to indacaterol maleate/mometasone furoate | Asthma | 28 | Apr 2008actual | 2013-04-22 |
| Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic SubjectsNCT00620230Routine safety observations and pharmacokinetic measurementsRandomized · Double-masked | Phase 1 | Completed | Drug: NVP-VAK694, NVP-VAK694 | Allergic Rhinitis | 46 | Apr 2008actual | 2010-09-27 |
| Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 MonthsNCT00649883To evaluate the safety and tolerability of one and two doses of investigational vaccines or active control influenza vaccine in unprimed healthy children aged 6 months to <36 months.Randomized · Single-masked · Prevention | Phase 2 | Completed | Biological: Influenza Trivalent Inactivated vaccines Novartis, Influenza Trivalent Inactivated vaccines | Influenza | 360 | Apr 2008actual | 2017-04-07 |
| Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)NCT00409708results2011-05-17The Number of Chromosomal Aberrations Per 100 Cells Excluding Gaps at Baseline and at the End of Treatment i.e Day 84 (Week 12)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy · Behavioral: Behavior Therapy | Attention Deficit Hyperactivity Disorder | 142 | Mar 2008actual | 2011-05-17 |
| Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's DiseaseNCT00428389results2011-06-27Number of Participants Who Discontinued From the Study Due to Any Reason During the Core Phase of the StudyRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch | Alzheimer's Disease | 262 | Feb 2008actual | 2014-06-11 |
| Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.NCT00568503Safety, tolerability and pharmacodynamics of a single dose of QAX028 compared to tiotropium bromide 18μg and to placebo.Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: QAX028, Placebo, Tiotropium bromide, QAX028, QAX028 | COPD | 29 | Feb 2008actual | 2011-04-28 |
| Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and AdolescentsNCT00645411results2013-01-16Geometric Mean Titers of the Cell Culture-derived Vaccine Compared With the Egg-derived Vaccine in 3 to 8 Year-old ChildrenRandomized · Single-masked · Prevention | Phase 2/3 | Completed | Biological: Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV), Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV) | Influenza | 3,604 | Feb 2008actual | 2015-11-23 |
| Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic HypertensionNCT00170950results2011-05-17Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality EventRandomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment. | Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Hypertension | 11,506 | Jan 2008actual | 2023-10-24 |
| Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic AsthmaNCT00267202results2011-05-16Number of Participants With Systemic Allergic Reactions (SAR) to Specific Immunotherapy (SIT)Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Placebo, Omalizumab, Immunotherapy, Immunotherapy | Allergic Asthma | 275 | Jan 2008actual | 2016-09-14 |
| Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)NCT00275821results2011-03-16Mean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 12Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Ranibizumab 0.3 mg - 3 times monthly, then quarterly, Ranibizumab 0.5 mg - 3 times monthly, then quarterly, Ranibizumab 0.3 mg monthly | Age Related Macular Degeneration | 353 | Jan 2008actual | 2011-03-16 |
| Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic FibrosisNCT00391976results2011-08-29Time to Recurrence of Pseudomonas (P.) Aeruginosa (Any Genotype) in Sputum or Deep Throat Cough SwabRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Tobramycin solution for inhalation 300 mg | Cystic Fibrosis | 123 | Jan 2008actual | 2011-08-29 |
| Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive DisorderNCT00411099To evaluate the change from Baseline to Week 8 on the total score of the clinician rated 17-Item Hamilton Depression Rating Scale (HAM-D17)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: agomelatine, placebo | Major Depressive Disorder | 508 | Jan 2008actual | 2020-12-23 |
| Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive DisorderNCT00411242Change from Baseline to Week 8 on the total score of the clinician rated 17-Item Hamilton Depression Rating Scale (HAM-D17)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: agomelatine, placebo | Major Depressive Disorder (MDD) | 503 | Jan 2008actual | 2020-12-23 |
| Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT00510510results2011-01-21Safety of Treatment With NVA237 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: NVA237 100 µg, Placebo, NVA237 200 µg | Chronic Obstructive Pulmonary Disease (COPD) | 281 | Jan 2008actual | 2012-05-21 |
| Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic DermatitisNCT00367393• Decrease of the Dermatophot (a combination of a dermatoscope and a camera) score on skin deterioration and spider veins from baseline to end of the studyNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Pimecrolimus cream 1% | Atopic Dermatitis | 41 | Dec 2007actual | 2017-02-24 |
| Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive PatientsNCT00396656results2011-06-06Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Injected Sites Compared to NaCl Injected SitesRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Atenolol, Hydrochlorothiazide (HCTZ)), Valsartan | Hypertension | 30 | Dec 2007actual | 2011-06-06 |
| Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)NCT00428792results2011-05-06Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Teacher Rating in the Intent-to-Treat (ITT) PopulationRandomized · Single-masked · Treatment | Phase 3 | Completed | Drug: Methylphenidate 20 mg long-acting capsules | Attention Deficit Hyperactivity Disorder | 150 | Dec 2007actual | 2011-05-06 |
| Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled HypertensionNCT00523744results2011-05-25Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the StudyNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Amlodipine, Olmesartan medoxomil, Amlodipine+valsartan, Hydrochlorothiazide | Hypertension | 257 | Dec 2007actual | 2020-08-04 |
| Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel in Patients With Acute Ankle SprainNCT00573768results2010-11-18Pain on Movement on Day 5 (Change From Baseline). A Greater Change From Baseline on Day 5 Equates to a Better Outcome.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Diclofenac diethylamine 2.32% gel, Placebo, Diclofenac diethylamine 2.32% gel / Placebo | Ankle Sprain | 271 | Dec 2007actual | 2012-04-20 |
| Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)NCT00138632Safety as assessed by visual acuity measurements, ophthalmic examinations, vital signs, laboratory assessments, and adverse events up to 12 monthsRandomized · Triple-masked · Treatment | Phase 1/2 | Completed | Drug: PTK787, PTK787, Placebo | Wet Age-Related Macular Degeneration | 50 | Nov 2007actual | 2008-11-14 |
| Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in HypertensionNCT00400777Proportion of patients reaching diastolic BP control, Proportion of patients reaching systolic BP control Percentage of diastolic responders,Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Valsartan, hydrochlorothiazide and amlodipine | Hypertension | 460 | Nov 2007actual | 2008-06-18 |
| Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With HypertensionNCT00413049results2011-02-08Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Valsartan/amlodipine 80/5 mg, Amlodipine 5 mg | Hypertension | 698 | Nov 2007actual | 2011-04-29 |
| Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With AliskirenNCT00441064results2011-03-25Mean 24 Hour Ambulatory Systolic Blood Pressure (MASBP) in Systolic Hypertensive Patients Treated With Aliskiren (300 mg) for 4 Weeks on a High Sodium Diet Versus 4 Weeks on a Low Sodium DietRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Aliskiren | Hypertension | 132 | Nov 2007actual | 2011-03-25 |
| Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure InfectionsNCT00463801results2010-12-23Proportion of Participants With Clinical Success at the Day 7 (D7) and Day 14 (D14) Visit After Treatment StartNon-randomized · Open-label · Treatment | Phase 4 | Terminatedsponsor's stated reason: Because of inadequate accrual. | Drug: Daptomycin | Staphylococcal Skin Infections | 52 | Nov 2007actual | 2011-03-24 |
| Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired PatientsNCT00572650Pharmacokinetic measuresOpen-label · Treatment | Phase 1 | Completed | Drug: vildagliptin | Type 2 Diabetes Mellitus | 29 | Nov 2007actual | 2012-05-02 |
| Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With HypertensionNCT00171054results2011-05-03Change From Baseline to Week 38 in the Carotid-femoral Pulse Wave Velocity (PWV)Randomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: Valsartan 320 mg, Amlodipine 10 mg, Hydrochlorothiazide | Hypertension | 125 | Oct 2007actual | 2011-06-06 |
| Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)NCT00394173Satisfactory relief of IBS-related abdominal pain/discomfortRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: DNK333, Placebo | Irritable Bowel Syndrome With Diarrhea (IBS-D) | 180 | Oct 2007actual | 2017-02-27 |
| Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00403845results2011-08-17Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 22 to 24 Hours Post-dose on Day 2Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Indacaterol 150 μg, Indacaterol 300 μg, Placebo | Chronic Obstructive Pulmonary Disease | 50 | Oct 2007actual | 2011-08-17 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male VolunteersNCT00421226Safety and tolerabilityRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: ACZ885 | Healthy | 48 | Oct 2007actual | 2012-04-30 |
| Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients HypertensionNCT00425997-Change from baseline in mean 24-hr ambulatory systolic blood pressure (BP) after 10 weeks of treatment of valsartan/HCTZ versus amlodipine and HCTZRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Valsartan/HCTZ, amlodipine, HCTZ | Hypertension | 480 | Oct 2007actual | 2011-06-08 |
| The Effect of Fluvastatin XL® Treatment in Patients With Metabolic SyndromeNCT00664742results2011-05-17Change in Total Cholesterol (TC), High Density Lipoprotein-Cholesterol (HDL-C), Low Density Lipoprotein-Cholesterol (LDL-C) and Triglycerides (TG) Levels From Baseline to Week-6Open-label · Treatment | Phase 4 | Completed | Drug: Fluvastatin XL® | Metabolic Syndrome | 614 | Oct 2007actual | 2011-05-17 |
| A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/LevodopaNCT00134966Symptom control change from baseline to week 39Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) | Parkinson's Disease | 493 | Sep 2007actual | 2017-05-17 |
| Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)NCT00338936Assessment of safety through reporting of adverse events, serious adverse events and deaths over 52 weeks.Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Valsartan + Hydrochlorothiazide | Hypertension | 362 | Sep 2007actual | 2011-11-08 |
| Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 DiabetesNCT00390520Glucagon counterregulatory response to hypoglycemia of the last 30 min of the 2.5 mM hypoglycemic clamp after 4 weeks treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Vildagliptin | Diabetes Mellitus, Type 2 | 28 | Sep 2007actual | 2020-02-11 |
| Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 MonthsNCT00487123Compliance rate at month 3, 6 and post study month 1 will be assessed by pill countRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Valsartan+/- Hydrochlorothiazide | Hypertension | — | Sep 2007actual | 2008-06-17 |
| Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial SeizuresNCT00275912Epileptic activity at electroencephalography in restNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Oxcarbazepine | Epilepsy, Partial Seizures | 60 | 2007-09-28actual | 2017-02-23 |
| Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart FailureNCT00171106Change in baseline exercise test after 15-42 days and 14 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: valsartan | Diastolic Dysfunction, Symptomatic Heart Failure | 150 | Aug 2007actual | 2016-11-18 |
| VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal WomenNCT00171132Change from baseline in exercise capacity measured by oxygen consumption during exercise testing, after 26 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: valsartan, atenolol, hydrochlorothiazide | Hypertension | 64 | Aug 2007actual | 2017-02-23 |
| 8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe HypertensionNCT00327587Change from baseline diastolic blood pressure after 8 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Valsartan + amlodipine, Valsartan + HCTZ, Amlodipine + HCTZ, Valsartan + amlodipine + HCTZ | Hypertension | 2,279 | Aug 2007actual | 2011-11-08 |
| Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With HypertensionNCT00387517Mean sitting diastolic blood pressure lowering effect at baseline, and week 8.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Aliskiren/HCTZ | Hypertension | 726 | Aug 2007actual | 2017-02-07 |
| Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium DietNCT00518765Renal plasma flow following 3 single doses of aliskiren in healthy volunteers on a low sodium(10 mEq/day)dietRandomized · Single-masked · Basic science | Phase 3 | Completed | Drug: Aliskiren, Aliskiren plus placebo, Aliskiren, Aliskiren plus placebo | Hypertension | 32 | Aug 2007actual | 2010-10-06 |
| Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I DisorderNCT00139594Safety and tolerability of treatment with licarbazepine over 52 weeks.Open-label · Treatment | Phase 4 | Completed | Drug: licarbazepine | Bipolar Disorder | 181 | Jul 2007actual | 2017-03-28 |
| Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant RecipientsNCT00170885Renal function assessed by glomerular filtration rate before and during the first 6 months of treatmentRandomized · Open-label · Prevention | Phase 4 | Completed | Drug: Everolimus | Kidney Transplantation | — | Jul 2007actual | 2016-11-16 |
| Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome PatientsNCT00171548observational | — | Completed | — | Metabolic Syndrome | 600 | Jul 2007actual | 2008-09-22 |
| An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.NCT00228059Safety and tolerability of licarbazepine with respect to adverse events, serious adverse events, changes in laboratory values, ECGs and vital signs.Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Licarbazepine | Bipolar I Disorder | 132 | Jul 2007actual | 2017-02-23 |
| An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United StatesNCT00237263Incidence of adverse events during the long term treatment (maximum 3 years)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Entacapone | Parkinson's Disease | 285 | Jul 2007actual | 2024-01-11 |
| An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I DisorderNCT00238485Safety and tolerability of licarbazepine with respect to adverse events, serious adverse events, changes in laboratory values, ECGs and vital signs.Non-randomized · Open-label · Diagnostic | Phase 3 | Completed | Drug: Licarbazepine | Bipolar I Disorder | 251 | Jul 2007actual | 2017-03-28 |
| A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive PatientsNCT00386139Mean Sitting Diastolic Blood Pressure lowering effect at baseline, and week 8.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Aliskiren/HCTZ | Hypertension | 881 | Jul 2007actual | 2017-02-07 |
| Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years OldNCT00464672results2010-05-05Percentage of Subjects With Seroprotection, in Healthy Adults 18 to 64 Years of AgeRandomized · Double-masked · Prevention | Phase 3 | Completed | Biological: Influenza virus vaccine, Comparator influenza vaccine | Influenza | 1,893 | Jul 2007actual | 2015-10-01 |
| Trial to Evaluate the Efficacy of Fluvastatin on Certain MarkersNCT00171262Change from baseline in serum inflammatory markers after 52 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Fluvastatin | Dyslipidemia | 120 | Jun 2007actual | 2017-02-23 |
| Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic SyndromeNCT00394745To evaluate the effect of valsartan 320 mg on small, dense low density lipoprotein (LDL) subfractions in hypertensive patients with metabolic syndrome.Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Valsartan | Hypertension, Metabolic Syndrome | 45 | Jun 2007actual | 2017-02-24 |
| VALIDATE Valsartan and Supportive Measures - Impact on Drug Adherence of Treated Hypertensive PatientsNCT00394823Drug adherence in patients (daily proportion of patients taking one tablet of the prescribed hypertensive therapy as prescribed)Randomized · Open-label · Other | Phase 3 | Completed | Behavioral: Set of supportive tools/measures vs. standard care | Hypertension | 206 | Jun 2007actual | 2017-05-18 |
| A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild HyperglycemiaNCT00300287Change from baseline in HbA1c at 108 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Vildagliptin | Diabetes Mellitus, Type 2 | 150 | 2007-06-26actual | 2017-08-02 |
| Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis BNCT00128544Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: telbivudine, valtorcitabine | Hepatitis B | 130 | May 2007actual | 2017-06-16 |
| VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With MicroalbuminuriaNCT00171067Change from baseline in urinary albumin excretion after 30 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: valsartan, lisinopril | Hypertension | 134 | May 2007actual | 2017-05-17 |
| A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder PatientsNCT00219102Change from baseline in diastolic blood pressure after 12 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: aliskiren | Hypertension, Diabetes | 336 | May 2007actual | 2020-02-11 |
| SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal DysfunctionNCT00299832Adverse events after 8 weeksNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Aliskiren | Hypertension | 40 | May 2007actual | 2016-11-18 |
| Maintaining Bone Strength in Men With Prostate CancerNCT00391950Change in bone mineral density (BMD) at lumbar spine as assessed by dual energy x-ray absoptiometry (DEXA) scanRandomized · Open-label · Treatment | Phase 3 | Terminated | Drug: Zoledronic acid | Prostate Cancer | 300 | May 2007actual | 2009-11-23 |
| Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.NCT00414024To evaluate the long term safety of tegaserodNon-randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: This study was terminated early as a result of regulatory action suspending tegaserod use in 2007 | Drug: Tegaserod | Opioid-induced Constipation | 11 | May 2007actual | 2012-04-20 |
| Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)NCT00443482• Efficacy assessed by 12 hour Area Under the Curve (AUC) of FEV1 (forced expiratory volume in 1 second, is a measure of how well the lungs are working)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: formoterol | Asthma | 50 | May 2007actual | 2017-03-28 |
| Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 DiabetesNCT00138619Safety during 104 weeks of treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: vildagliptin | Diabetes Mellitus, Type 2 | 478 | Apr 2007actual | 2012-05-07 |
| Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential HypertensionNCT00344110Mean sitting diastolic blood pressure (msDBP) lowering from baseline to the study end to placebo and losartanRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Aliskiren | Hypertension | 768 | Apr 2007actual | 2016-11-18 |
| Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation PatientsNCT00348634Orocecal transit: Time of radioactive marker to reach the cecum using scintigraphyRandomized · Double-masked · Treatment | Phase 4 | Terminatedsponsor's stated reason: Terminated early due to regulatory action suspending tegaserod use in 2007 | Drug: Tegaserod | Chronic Constipation | 60 | Apr 2007actual | 2016-03-04 |
| Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II HypertensionNCT00350168Change from baseline in MSSBP at week 4Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: valsartan + amlodipine | Hypertension | 647 | Apr 2007actual | 2016-11-18 |
| Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II HypertensionNCT00353912Change from baseline in MSSBP at week 8Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: valsartan + amlodipine | Hypertension | 571 | Apr 2007actual | 2016-11-18 |
| Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer PainNCT00365820Change from baseline in the number of bowel movements over weeks 1-4Randomized · Double-masked · Treatment | Phase 2/3 | Terminatedsponsor's stated reason: This study was terminated early as a result of regulatory action suspending tegaserod use in 2007 | Drug: Tegaserod | Constipation | 670 | Apr 2007actual | 2012-04-20 |
| Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 DiabetesNCT00380445To explore whether vildagliptin augments insulin mediated inhibition of adipose tissue lipid mobilization following a mixed meal in patients with type 2 diabetesRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Vildagliptin | Diabetes Mellitus, Type 2 | 21 | Apr 2007actual | 2017-02-23 |
| Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.NCT00399659Long term safety of tegaserodNon-randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: This study was terminated early as a result of regulatory action suspending tegaserod use in 2007 | Drug: Tegaserod | Opioid-induced Constipation | 360 | Apr 2007actual | 2012-05-01 |
| STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous LeukemiaNCT00006343Treatment | Phase 3 | Completed | Biological: recombinant interferon alfa · Drug: cytarabine, imatinib mesylate | Leukemia | — | Mar 2007actual | 2013-01-03 |
| Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced CancerNCT00171587SafetyNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: PTK787/ZK 222584 (vatalanib) | Tumors, Neoplasm Metastasis | 22 | Mar 2007actual | 2009-11-19 |
| Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant TherapyNCT00247650Clinical response at 24 weeksRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: Zoledronic Acid; Letrozole | Breast Cancer | 190 | Mar 2007actual | 2017-03-01 |
| Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular DegenerationNCT00284089results2011-02-11Mean Change From Baseline in the Best Corrected Visual Acuity Score of the Study Eye at Month 6 in Group BRandomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Ranibizumab | Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD) | 88 | Mar 2007actual | 2011-02-24 |
| Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current MonotherapyNCT00351130Percentage of patients who reach BP goal, systolic <140 mmHg and diastolic <90 mmHg, after 22 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: valsartan, amlodipine | Hypertension | 79 | Mar 2007actual | 2017-02-24 |
| Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic SyndromeNCT00385658High density lipoprotein cholesterol (HDL-C) measured at the end of each study period.Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Fluvastatin extended release, fenofibrate, Fixed combination simvastatin/ezetimibe | Dyslipidemia | 75 | Mar 2007actual | 2017-02-24 |
| Effect of Tegaserod on Gastric Emptying in Patients With Diabetic GastroparesisNCT00390975Proportion of patients treated with tegaserod that improve gastric emptying at Week 2 as compared with baseline via a solid phase technetium gastric emptying time (GET)Non-randomized · Open-label · Treatment | Phase 4 | Terminatedsponsor's stated reason: This study was terminated early as a result of regulatory action suspending tegaserod use in 2007 | Drug: Tegaserod | Gastroparesis, Diabetes | 40 | Mar 2007actual | 2012-05-04 |
| Effects of FTY720 on Heart and Lung Functions in Healthy VolunteersNCT00416845Effects of two doses of FTY720 on lung and cardiac (heart) functions in healthy volunteers.Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: FTY720 | Healthy | 39 | Mar 2007actual | 2010-06-04 |
| Reducing the Overall Risk Level in Patients Suffering From Metabolic SyndromeNCT00821574Change in global risk from baseline to 3 and 9 months, as evaluated by the SCORE algorithmNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Fluvastatin, Valsartan, Hydrochlorothiazide | Hypertension, Dyslypidaemia | 144 | Mar 2007actual | 2017-03-01 |
| Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis SubjectsNCT00125346Forced expiratory volume in 1 second (FEV1) measured at week 1 and week 5.Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: per Data Monitoring Committee recommendation | Drug: Tobramycin Inhalation Powder | Cystic Fibrosis | 98 | Feb 2007actual | 2011-10-12 |
| Fluvastatin in the Therapy of Acute Coronary SyndromeNCT00171275Change from baseline in circulating markers of inflammation after 4 weeks and after 52 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Fluvastatin | Coronary Disease, Myocardial Infarction | 1,000 | Feb 2007actual | 2010-07-16 |
| "ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart FailureNCT00219011Measurement of safety information and tolerability of drug after 12 weeksRandomized · Double-masked · Other | Phase 3 | Completed | Drug: aliskiren | Heart Failure | 280 | Feb 2007actual | 2017-05-17 |
| Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 DiabetesNCT00237237Change from baseline in HbA1c at 52 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: vildagliptin | Diabetes Mellitus, Type 2 | 588 | Feb 2007actual | 2017-02-07 |
| A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive PatientsNCT00392262To investigate whether 4 weeks treatment with valsartan 160mg + amlo 5mg provide an add'l mean sitting systolic blood pressure reduction in patients not adequately responding to 4 weeks treatment with amlo 5mg or felodipine 5mgRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: valsartan + amlodipine | Hypertension | 224 | Feb 2007actual | 2016-11-18 |
| Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent AsthmaNCT00403637Lung function measured 24 hours after having taken medication, by a special test called "forced expiratory volume in 1 second "(FEV1)Randomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: indacaterol maleate | Asthma | 45 | Feb 2007actual | 2016-11-18 |
| Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.NCT00056459Progression free survivalRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Vatalanib | Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms | 1,168 | Jan 2007actual | 2020-02-10 |
| Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis BNCT00131742Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: telbivudine, lamivudine | Chronic Hepatitis B | — | Jan 2007actual | 2015-05-12 |
| Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)NCT00149968Changes in gastrointestinal symptom severity after conversion from MMF to enteric-coated mycophenolate sodiumNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS) | Renal Transplantation, Gastrointestinal Problems | 196 | Jan 2007actual | 2020-02-11 |
| Antialbuminuric Effects of Valsartan and LisinoprilNCT00171600Change from baseline in urine albumin excretion rate from collected urine samples, after 16 and 20 weeksRandomized · Open-label · Treatment | Phase 4 | Terminated | Drug: VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ | Hypertension, Early Diabetic Nephropathy | 54 | Jan 2007actual | 2011-11-08 |
| A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders PatientsNCT00219193Change from baseline in diastolic blood pressure after 8 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: aliskiren | Hypertension | 641 | Jan 2007actual | 2017-02-07 |
| A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart FailureNCT00294086Tolerability as assessed by laboratory tests for potassium, creatinine, and on systolic blood pressure, symptoms of low blood pressure, and symptoms of heart failureRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: valsartan 160 mg, valsartan 160 mg BID | Chronic Heart Failure | 160 | Jan 2007actual | 2011-06-08 |
| Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current MonotherapyNCT00304226Blood pressure less than 140/90 mmHg after 14 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: valsartan, amlodipine | Hypertension | 1,288 | Jan 2007actual | 2016-11-16 |
| A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on MonotherapyNCT00327145Blood pressure less than 140/90 mmHg in non diabetic patients or blood pressure less than 130/80 mmHg in diabetic patients after 16 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: valsartan, hydrochlorothiazide, amlodipine | Hypertension | 894 | Jan 2007actual | 2016-11-18 |
| Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.NCT00343551Mean 24-hour ambulatory diastolic blood pressure (MADBP) change from baseline, after a missed dose, aliskiren 300 mg versus irbesartan 300mg.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Aliskiren | Essential Hypertension | 654 | Jan 2007actual | 2017-02-23 |
| Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)NCT00396604Lung function measured 24 hours after having taken medication, by a special test called "forced expiratory volume in 1 second "(FEV1)Randomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: indacaterol maleate | Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive | 51 | Jan 2007actual | 2011-10-25 |
| Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis SiccaNCT0012824512 week's treatment with 2 concentrations of pimecrolimus (0.3% and 1 %)in one sign and one symptomRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Pimecrolimus, Vehicle | Keratoconjunctivitis Sicca | 440 | Dec 2006actual | 2020-05-27 |
| Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis BNCT00132652Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Lamivudine, Telbivudine | Chronic Hepatitis B | 240 | Dec 2006actual | 2017-02-23 |
| Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus HydrochlorothiazideNCT00360178Diastolic Blood Pressure (DBP) reduction by Valsartan + HCTZ in patients not adequately responding (i.e., DBP >= 90 mmHg) to 4 weeks of treatment with Candesartan + HCTZ in free combinationNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Valsartan plus Hydrochlorothiazide, Candesartan plus Hydrochlorothiazide, Amlodipine | Hypertension | 198 | Dec 2006actual | 2016-11-18 |
| Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving EverolimusNCT00134940observational | — | Completed | — | Coronary Heart Disease | 100 | Nov 2006actual | 2011-06-16 |
| Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk HypertensionNCT00139555Change from baseline in left ventricular mass index after 52 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: amlodipine/benazepril | Hypertension, Left Ventricular Hypertrophy | 125 | Nov 2006actual | 2017-02-23 |
| A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have HypertensionNCT00171028Change from baseline systolic blood pressure after 2 and 4 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: valsartan | Hypertension | 90 | Nov 2006actual | 2011-11-08 |
| A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional HemosiderosisNCT00171171Liver Iron Concentration (as measured by biopsy)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: deferasirox | Beta-Thalassemia, Hemosiderosis | 252 | Nov 2006actual | 2017-03-01 |
| A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood PressureNCT00260923Change from baseline in diastolic blood pressure after 8 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: aliskiren | Hypertension | 641 | Nov 2006actual | 2011-11-08 |
| SPP100 (Aliskiren) Regimen in Patients With Severe HypertensionNCT00299806Incidence of adverse events after 8 weeksNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Aliskiren | Hypertension | 39 | Nov 2006actual | 2016-11-18 |
| A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetesNCT00312130Change from baseline in acute insulin response to an iv glucose load at 6 weeksNon-randomized · Single-masked · Treatment | Phase 3 | Completed | Drug: Vildagliptin | Pre-diabetes | 20 | Nov 2006actual | 2016-11-18 |
| A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.NCT00380380Evaluate the effects of acute effects of vildagliptin on gastric emptyingRandomized · Single-masked · Treatment | Phase 3 | Completed | Drug: Vildagliptin | Diabetes Mellitus, Type 2 | 18 | Nov 2006actual | 2017-02-23 |
| Effect of Food on Bioavailability of Modified Release Formulations of ImatinibNCT00420043To compare the bioavailability of Modified Release formulations to 400 mg immediate release (IR) tablet when administered twice-daily (both given with a low fat meal).Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: imatinib | Healthy | 32 | Nov 2006actual | 2016-04-05 |
| Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 DiabetesNCT00461136To evaluate the time-course of the antiproteinuric effect of renin inhibition with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established nephropathy.Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Aliskiren | Diabetes Type 2 | 18 | Nov 2006actual | 2016-09-23 |
| Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip OsteoarthritisNCT00154219WOMAC 3.1 LK questionnaire after 13 weeks of treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Lumiracoxib (drug) | Osteoarthritis, Hip | 1,200 | Oct 2006actual | 2012-05-21 |
| Safety and Pharmacokinetics of LHT344 in Chinese Healthy SubjectsNCT00414778Pharmacokinetics of single and repeat daily oral dose of LHT344 in Chinese healthy subjectsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: LHT344 | Healthy | 12 | Oct 2006actual | 2011-01-13 |
| Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.NCT00171561Blood measures of hypertension after 24 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: valsartan/hydrochlorothiazide | Hypertension | 144 | Sep 2006actual | 2011-11-08 |
| Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood PressureNCT00219180Change from baseline in diastolic blood pressure after week 8Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: aliskiren | Hypertension | 1,797 | Sep 2006actual | 2017-05-17 |
| A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and HypercholesterolemiaNCT00254475Low density lipoproteins after 6 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: simvastatin, valsartan | Essential Hypertension, Hypercholesterolemia | 871 | Sep 2006actual | 2014-08-19 |
| A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)NCT00311740Change from baseline in diastolic blood pressure after 8 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Valsartan, Hydrochlorothiazide | Hypertension | 582 | Sep 2006actual | 2017-02-23 |
| Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis BNCT00115245Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Telbivudine (LdT), Adefovir Dipivoxil | Chronic Hepatitis B | — | Aug 2006actual | 2015-05-12 |
| Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 DiabetesNCT00138567Safety during 104 weeks of treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: vildagliptin | Diabetes Mellitus, Type 2 | 530 | Aug 2006actual | 2016-11-18 |
| Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) TherapyNCT00149942Gastro-intestinal adverse events before switch versus 3 months after switchNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Enteric-coated Mycophenolate sodium (EC-MPS) | Kidney Transplantation, Liver Transplantation | 23 | Aug 2006actual | 2016-11-18 |
| Atrial Fibrillation Feasibility Certoparin Trial - AFFECTNCT00171769Safety measures including reporting of serious adverse events and adverse events, including vascular and neurological eventsNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Certoparin | Persistent Nonvalvular Atrial Fibrillation | 200 | Aug 2006actual | 2017-02-23 |
| Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant PatientsNCT00239083patient and graft survivalRandomized · Open-label · Prevention | Phase 4 | Completed | Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS) | Kidney Transplantation | 40 | Aug 2006actual | 2017-02-23 |
| Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate HypertensionNCT00262236Change from baseline in diastolic blood pressure after 12 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Aliskiren | Hypertension | 693 | Aug 2006actual | 2016-11-18 |
| Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With HypertensionNCT00280540Change from baseline systolic blood pressure after 4 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Valsartan/Hydrochlorothiazide | Hypertension | 648 | Aug 2006actual | 2010-11-09 |
| Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 DiabetesNCT00120536Change from baseline in HbA1c at 24 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: vildagliptin | Diabetes Mellitus, Type 2 | 288 | Jul 2006actual | 2017-05-18 |
| Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 DiabetesNCT00138554Safety of vildagliptin in combination with pioglitazone during 52 weeks of treatmentRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: vildagliptin, pioglitazone | Diabetes Mellitus, Type 2 | 318 | Jul 2006actual | 2017-02-23 |
| Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%NCT00138593Safety in combination with pioglitizone after 52 weeks of treatmentNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: vildagliptin | Diabetes Mellitus, Type 2 | 180 | Jul 2006actual | 2017-03-01 |
| Antiproteinuric Effect of Valsartan and LisinoprilNCT00171574Change from baseline in urine protein excretion after 20 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Valsartan, Valsartan plus HCTZ, Lisinopril | Hypertension, Diabetic Nephropathy | 124 | Jul 2006actual | 2017-02-24 |
| An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's DiseaseNCT00219232Safety and tolerability as measured by adverse events, vital signs and skin irritation for up to 28 weeks treatmentNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Rivastigmine Transdermal Patch | Alzheimer's Disease | 868 | Jul 2006actual | 2017-02-23 |
| Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose ToleranceNCT00237250Change in area under the 0-2 hour prandial glucose curve at 12 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: vildagliptin | Prediabetic State | 171 | Jul 2006actual | 2012-05-07 |
| Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe HypertensionNCT00273299Blood pressure less than 140/90 mmHg after 4 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: valsartan plus hydrochlorothiazide | Hypertension | 607 | Jul 2006actual | 2011-11-08 |
| A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of AmlodipineNCT00294710Change from baseline in diastolic blood pressure after 52 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Aliskiren | Hypertension | 976 | Jul 2006actual | 2011-11-08 |
| Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus FelodipineNCT00367939To investigate whether 5 weeks of treatment with valsartan 160mg + amlodipine 10mg provide add'l mean sitting systolic BP reduction in patients not adequately responding to 5 weeks of treatment with ramipril + felodipine--i.e., mean systolic BPNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: valsartan + amlodipine | Hypertension | 132 | Jul 2006actual | 2017-05-18 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071NCT00409929Safety and tolerability of ascending single oral doses of AEB071 in healthy subjects.Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: AEB071 | Healthy | 16 | Jul 2006actual | 2010-10-19 |
| Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United StatesNCT00143026Quality of life assessmentRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: carbidopa, levodopa, entacapone | Parkinson's Disease | 184 | Jun 2006actual | 2017-03-29 |
| To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.NCT00170924Change from baseline in diastolic heart function at 38 weeks, measured by echocardiogramRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Valsartan | Diastolic Dysfunction, Hypertension | 317 | Jun 2006actual | 2011-11-08 |
| Safety of Diclofenac Sodium Gel in Knee OsteoarthritisNCT00171691Incidence of treatment-emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Diclofenac Topical Sodium Gel 1% | Osteoarthritis | 450 | Jun 2006actual | 2012-04-23 |
| Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)NCT00171938PFS (progression free-survival), defined by the percentage of patients without evidence of progressive disease in 6 monthsNon-randomized · Open-label · Treatment | Phase 2 | Terminated | Drug: imatinib mesylate | Glioblastoma | 30 | Jun 2006actual | 2017-02-24 |
| Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With DyspepsiaNCT00232089Over 6 weeks of treatment assessment of percent of days with satisfactory relief of dyspepsia and/or average severity score in (average of postprandial fullness early satiety and bloating)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Tegaserod | Dyspepsia | 1,296 | Jun 2006actual | 2016-11-18 |
| Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant RecipientsNCT002389536 Month evaluationNon-randomized · Open-label · Prevention | Phase 4 | Completed | Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS) | Renal Transplantation | 30 | Jun 2006actual | 2017-02-23 |
| A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.NCT00250562Change from baseline diastolic blood pressure after 8 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: valsartan plus hydrochlorothiazide | Hypertension | 1,171 | Jun 2006actual | 2017-08-01 |
| Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic AsthmaNCT00482248Safety assessed by adverse events, serious adverse events, hematology, blood chemistry and urinalysis value, vital signs data, the performance of physical examinations and body weight measurements.Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Omalizumab | Asthma | 132 | Jun 2006actual | 2016-11-18 |
| Rivastigmine Capsules in Patients With Probable Vascular DementiaNCT00130338Safety and tolerability of rivastigmine for up to 52 weeks of treatment in patients with VaD and probable VaDNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Rivastigmine | Vascular Dementia | 521 | May 2006actual | 2017-03-28 |
| Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 DiabetesNCT00138515Safety of vildagliptin in combination with metformin during 52 weeks of treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: vildagliptin | Diabetes Mellitus, Type 2 | 418 | May 2006actual | 2017-03-01 |
| Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.NCT00170742regression of neovascularization.Randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: trial stopped on Sept 24, 2007 | Drug: Octreotide, 30 mg i.m. LAR formulation | Proliferative Diabetic Retinopathy | 17 | May 2006actual | 2008-08-12 |
| Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant RecipientsNCT00239070To assess patient and graft survival, acute rejection incidence, graft function and specific pertinent safety parameters in de novo renal transplant recipients.Non-randomized · Open-label · Prevention | Phase 3 | Completed | Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS) | Renal Transplantation | 69 | May 2006actual | 2011-01-31 |
| Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney RecipientsNCT00240955Safety and tolerability of enteric-coated mycophenolate sodium based on adverse event (AE) reporting.Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Enteric-coated Mycophenolate sodium (EC-MPS) | Renal Transplantation | 79 | May 2006actual | 2017-02-23 |
| A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis BNCT00057265Primary efficacy endpoint: "therapeutic response", defined as reduction of serum HBV DNA to below 5 log10 copies/mL, coupled with normalization of serum alanine aminotransferase levels OR loss of detectable serum HBeAg.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: telbivudine or lamivudine | Chronic Hepatitis B | — | Apr 2006actual | 2015-03-20 |
| Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary HypercholesterolemiaNCT00136799Percent change from baseline in low density lipoprotein cholesterol after 12 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Fluvastatin | Mixed Dyslipidemia, Hypercholesterolemia | 325 | Apr 2006actual | 2017-02-23 |
| Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 DiabetesNCT00138541Safety of vildagliptin during 52 weeks of treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: vildagliptin | Diabetes Mellitus, Type 2 | 440 | Apr 2006actual | 2017-03-01 |
| Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 DiabetesNCT00138580Safety of vildagliptin in combination with glimepiride during 52 weeks of treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: vildagliptin | Diabetes Mellitus, Type 2 | 345 | Apr 2006actual | 2017-03-01 |
| A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.NCT00154245Graft function 6 months post transplantationNon-randomized · Open-label · Prevention | Phase 4 | Completed | Drug: Enteric-Coated Mycophenolate sodium (EC-MPS) | Kidney Transplantation | 20 | Mar 2006actual | 2017-02-23 |
| A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic SyndromeNCT00170937Change from baseline in insulin sensitivity after 16 weeksRandomized · Double-masked · Prevention | Phase 4 | Completed | Drug: valsartan plus hydrochlorothiazide | METABOLIC SYNDROME, HYPERTENSION, PRE-HYPERTENSION | 507 | Mar 2006actual | 2016-11-18 |
| A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of AgeNCT00171041Change from baseline in sitting systolic blood pressure after 2 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: valsartan | Hypertension | 265 | Mar 2006actual | 2016-11-18 |
| VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term HemodialysisNCT00171080Change from baseline in systolic blood pressure after 4 weeksRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: valsartan, irbesartan | Hypertension | 86 | Mar 2006actual | 2017-05-18 |
| Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation RecipientsNCT00171496Incidence of NODM or impaired fasting glucose (IFG) in de novo kidney transplant patients receiving cyclosporine microemulsion versus in patients receiving tacrolimus within the first 6 months post-transplantation.Randomized · Open-label · Prevention | Phase 4 | Completed | Drug: Cyclosporine microemulsion, Tacrolimus | Kidney Transplant | 693 | Mar 2006actual | 2016-11-18 |
| Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients.NCT00171756Change from baseline in a clinical laboratory measurement of a blood clotting factor after 12 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: valsartan/atenolol | Hypertension | 92 | Mar 2006actual | 2017-02-23 |
| A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.NCT00219063Change from baseline in diastolic blood pressure after 26 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: aliskiren | Hypertension | 844 | Mar 2006actual | 2017-05-17 |
| A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mgNCT00219115Change from baseline in mean sitting diastolic blood pressure after 8 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: aliskiren | Hypertension | 493 | Mar 2006actual | 2017-02-07 |
| Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.NCT00219323Safety of omalizumabNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Omalizumab | Asthma | 133 | Mar 2006actual | 2011-10-25 |
| Other Effects of Fluvastatin Are Investigated in Patients With Metabolic SyndromeNCT00138528Change from baseline in circulating marker of inflammation (C-reactive protein) after 5 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Fluvastatin | Metabolic Syndrome | 55 | Feb 2006actual | 2017-02-23 |
| Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI IntoleranceNCT00150020Tolerability of EC-MPS in combination with CsA-ME or tacrolimus as determined by gastrointestinal symptom rating scale (GSRS) after conversion from MMF in maintenance renal transplant patients with GI intoleranceNon-randomized · Open-label · Prevention | Phase 4 | Completed | Drug: Enteric-coated mycophenolate sodium (EC-MPS) | Renal Transplantation | 728 | Feb 2006actual | 2008-01-24 |
| A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mgNCT00171405Assessment of safety through reporting of adverse events and serious adverse events, including deaths, following a 12 month studyNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: aliskiren | Hypertension | 250 | Feb 2006actual | 2016-11-18 |
| A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood PressureNCT00219167Change from baseline in average 24 hour systolic ambulatory blood pressure after 8 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: aliskiren | Hypertension | 355 | Feb 2006actual | 2016-11-18 |
| Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 DiabetesNCT00138606Safety of vildagliptin in combination with insulin during 52 weeks of treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: vildagliptin | Diabetes Mellitus, Type 2 | 179 | Jan 2006actual | 2016-11-18 |
| The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.NCT00154323Duration of remissionRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Oxcarbazepine | Bipolar Disorder | 55 | Jan 2006actual | 2023-12-14 |
| A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and HypercholesterolemiaNCT00171093Change in average ambulatory systolic blood pressure over 24 hoursRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: valsartan + simvastatin | HYPERTENSION, HYPERCHOLESTEROLEMIA | 369 | Jan 2006actual | 2017-02-23 |
| Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant RecipientsNCT00171743Non-randomized · Open-label · Prevention | Phase 4 | Completed | Drug: Cyclosporine microemulsion | Liver Transplant | 47 | Jan 2006actual | 2017-06-07 |
| A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of AmlodipineNCT00219154Change from baseline in diastolic blood pressure after 26 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: aliskiren | Hypertension | 1,125 | Jan 2006actual | 2011-11-08 |
| Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft RecipientsNCT00228020Time to first BPAR episode or treatment failureRandomized · Double-masked · Prevention | Phase 3 | Completed | Drug: basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent), MMF, cyclosporine, steroids | Pediatric Kidney Transplantation | 212 | Jan 2006actual | 2010-08-25 |
| Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under OcclusionNCT00925730Pimecrolimus blood concentrationOpen-label · Treatment | Phase 4 | Completed | Drug: Pimecrolimus | Atopic Dermatitis | 20 | Jan 2006actual | 2016-11-18 |
| Fluvastatin in Adults With Dislipidemia With History of Muscle ProblemsNCT00125125Change from baseline in low density lipoprotein cholesterol after 12 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Fluvastatin | Dyslipidemia | 218 | Dec 2005actual | 2017-05-17 |
| Octreotide Acetate in Microspheres in Patients With Diabetic RetinopathyNCT00130845time to progression of diabetic retinopathyRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Octreotide Acetate in Microspheres, Placebo | Diabetic Retinopathy | 312 | Dec 2005actual | 2011-11-17 |
| Octreotide Acetate in Microspheres in Patients With Diabetic RetinopathyNCT00131144time to progression of diabetic retinopathyRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres, Placebo | Diabetic Retinopathy | 583 | Dec 2005actual | 2011-11-17 |
| Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients With New Onset Diabetes After the 3rd Month Post-transplantNCT00171717% of patients whose diabetes resolves 6 months after the conversion (fasting glucose < 1.26 g/L without hypoglycemic treatment).Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Cyclosporine - cyclosporine microemulsion | Maintenance Liver Transplant Patients With New Onset Diabetes | 39 | Dec 2005actual | 2011-02-01 |
| Persistence of Immune Response After Vaccination With MCCNCT00310687persistence of memory response to N. meningitidis serogroup C as measured by serum bactericidal activity at one year after either a challenge with 1/5 of a dose of Meningococcal A/C Polysaccharide vaccine or a booster dose of MenC Vaccine.Non-randomized · Open-label · Prevention | Phase 4 | Completed | Procedure: BLOOD DRAW | Prevention of Meningococcal Infection | 1,244 | Dec 2005actual | 2014-09-19 |
| 52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or SpineNCT00145301To show that either regimen of lumiracoxib (100mg od or 100mg bid) is not inferior to celecoxib 200mg od with respect to retention rate at 1 year in pts suffering from primary OA in hip, knee, hand or spine.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Lumiracoxib | Osteoarthritis | 3,036 | Nov 2005actual | 2012-05-21 |
| A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe HypertensionNCT00219050Evaluate safety through adverse events and laboratory abnormalities after 8 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: aliskiren | Hypertension | 180 | Nov 2005actual | 2011-02-25 |
| Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With HypertensionNCT00277472Blood pressure control (systolic blood pressure <140 and diastolic blood pressure <90mmHg) after 4 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Valsartan/Hydrochlorothiazide, HCTZ | Hypertension | 300 | Nov 2005actual | 2011-06-07 |
| Kinetics of B Cell Response in Infants Menjugate VaccinationNCT00310700To establish at which day meningococcal C specific B cells are detectable in the blood of healthy infants following first and third immunisation with MenC Conjugate Vaccine as determined by Men C specific B-cell ELISPot assay.Non-randomized · Open-label · Prevention | Phase 4 | Completed | Biological: Meningococcal C conjugate vaccine | Prevention of Meningococcal Infection | 75 | Nov 2005actual | 2014-09-19 |
| A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 DiabetesNCT00351546Effect on insulin sensitivity at 6 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Vildagliptin | Diabetes Mellitus, Type 2 | 12 | Nov 2005actual | 2012-05-07 |
| A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus SheddingNCT00129818Group 1. Reduction of HSV DNA PCR positive days in HSV-2 seropositive patients with a history of clinical genital herpes lesionsRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Famciclovir | Genital Herpes | — | Oct 2005actual | 2012-04-27 |
| Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic ConjunctivitisNCT00133627Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Ketotifen | Seasonal Allergic Conjunctivitis | 229 | Oct 2005actual | 2011-11-17 |
| Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes MellitusNCT00136773Change from baseline in the urine albumin/creatinine ratio after 52 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: amlodipine/benazepril | Albuminuria | 332 | Oct 2005actual | 2011-03-09 |
| To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal WomenNCT00145275Temperature increaseRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: zoledronic acid | Osteopenia | 455 | Oct 2005actual | 2012-04-27 |
| Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsionNCT00150085Proportion of patients who no longer require a hypoglycemic agent, or who move from insulin to an oral agent, or who no longer meet the American Diabetes Association criteria, or a relative improvement in mean glycosylated hemoglobin at 12 and 26 weeksRandomized · Open-label · Treatment | Phase 4 | Terminated | Drug: cyclosporine micro-emulsion | Tacrolimus-associated Abnormal Glucose Metabolism in Kidney and Liver Transplant Recipients | 50 | Oct 2005actual | 2011-02-18 |
| Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant RecipientsNCT00171509Investigation of the proportion of patients with an improving GFR in the groups converted to OAD in comparison with the BID group 15 weeks after conversion.Randomized · Open-label · Prevention | Phase 4 | Completed | Drug: Cyclosporine microemulsion | Liver Transplant | 61 | Oct 2005actual | 2011-02-01 |
| A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity PatientsNCT00171613Change from baseline in BMINon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Octreotide | Hypothalamic Obesity | 32 | Oct 2005actual | 2012-04-30 |
| Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential HypertensionNCT00219037Adverse events, laboratory abnormalities, serious adverse eventsRandomized · Single-masked · Treatment | Phase 3 | Completed | Drug: aliskiren | Hypertension | 1,955 | Oct 2005actual | 2011-11-08 |
| A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders PatientsNCT00219076Change from baseline in mean sitting diastolic blood pressure after 6 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: aliskiren | Hypertension | 504 | Oct 2005actual | 2017-05-18 |
| Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant RecipientsNCT00312143patient and graft survivalNon-randomized · Open-label · Prevention | Phase 4 | Completed | Drug: Enteric-coated Mycophenolate sodium (EC-MPS) | De Novo Kidney Transplant Recipients | 35 | Oct 2005actual | 2011-02-02 |
| Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma PatientsNCT00482508Safety assessed by adverse events, serious adverse events, vital signs and laboratory safety data. A blood sample will be collected at each scheduled visit prior to administration of study medication and analyzed for free and total IgE levels and totalNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Omalizumab | Asthma | 95 | Oct 2005actual | 2011-10-25 |
| Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)NCT00129831Safety variables (laboratory tests, ECG, adverse events)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: QAB149 | COPD | 6 | Sep 2005actual | 2011-10-25 |
| Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial DysfunctionNCT00171327Percent change from baseline in brachial artery flow-mediated vasodilation after 8 weeksRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: valsartan, fluvastatin | Hypertension, Dyslipidemia | 213 | Sep 2005actual | 2011-11-08 |
| A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood PressureNCT00171353Change from baseline in urine albumin excretion after 24 weeksNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: valsartan | Hypertension | 109 | Sep 2005actual | 2011-11-08 |
| Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic AcidNCT00172029Percentage of patients showing complete response in bone pain palliation without having any analgesic treatmentRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Zoledronic acid | Breast Cancer With Metastatic Bone Disease | 116 | Sep 2005actual | 2023-08-18 |
| Extension Study of Enteric-coated Mycophenolate Sodium in Combination With Full Dose or Reduced Dose Cyclosporine Microemulsion in Patients With de Novo Kidney TransplantsNCT00238940Efficacy based on level of serum creatinine and calculated creatinine clearance 6 months post transplantation.Non-randomized · Open-label · Prevention | Phase 3 | Completed | Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS) | Renal Transplantation | 55 | Sep 2005actual | 2011-01-31 |
| A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 DiabetesNCT00351585Change from baseline in maximal insulin secretory capacity at 12 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Vildagliptin | Diabetes Mellitus, Type 2 | 39 | Sep 2005actual | 2012-05-07 |
| Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)NCT00699166Change from baseline in average stool form score at 2 weeksRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: DNK333 | Irritable Bowel Syndrome | 135 | Sep 2005actual | 2008-06-17 |
| A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With AsthmaNCT00130351Device use: Patients were instructed to record the number appearing in the dose counter window after their dose on the diary card.Non-randomized · Open-label · Other | Phase 3 | Completed | Device: formoterol | Asthma | 155 | Aug 2005actual | 2023-05-19 |
| Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin AloneNCT00171288Change from baseline in low density lipoprotein cholesterol after 12 weeksRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: fluvastatin, ezetimibe | Dyslipidemia | 83 | Aug 2005actual | 2011-11-08 |
| Efficacy and Safety of Diclofenac Sodium Gel in Knee OsteoarthritisNCT00171678WOMAC pain score in target knee at Week 12Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Diclofenac Topical Sodium Gel 1% | Osteearthritis | 480 | Aug 2005actual | 2012-04-23 |
| A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.NCT00219089Change from baseline in mean sitting diastolic blood pressure after 8 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: aliskiren | Hypertension, Diabetes Mellitus | 839 | Aug 2005actual | 2017-05-17 |
| Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes MellitusNCT00241085Change from baseline in urinary protein excretion after 30 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: valsartan | PROTEINURIA, Hypertension, Type 2 Diabetes | 392 | Aug 2005actual | 2011-11-08 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With MethotrexateNCT00619905Adverse events and infections occurrence throughout the study.Randomized · Double-masked · Treatment | Phase 1/2 | Completed | Drug: ACZ885, ACZ885 | Rheumatoid Arthritis | 53 | Aug 2005actual | 2008-02-21 |
| 6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid ArthritisNCT00170872Assess safety and tolerability profile of lumiracoxib in comparison to baselineNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Lumiracoxib | Osteoarthritis, Rheumatoid Arthritis | 135 | Jul 2005actual | 2012-05-21 |
| Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan AloneNCT00170989Change from baseline in diastolic blood pressure from baseline after 8 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: valsartan plus hydrochlorothiazide | Hypertension | 2,714 | Jul 2005actual | 2011-11-08 |
| A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.NCT00171366Change from baseline in mean sitting diastolic blood pressure at week 6Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: amlodipine/benazepril | Hypertension | 1,422 | Jul 2005actual | 2016-04-06 |
| Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver TransplantationNCT0023890112-month cumulative incidence of post-surgical graft loss and deathRandomized · Open-label · Prevention | Phase 3 | Completed | Drug: Basiliximab | Liver Transplant | 194 | Jul 2005actual | 2010-09-01 |
| Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant PatientsNCT00239018To assess glomerular filtration rate at month 3 post transplantationNon-randomized · Open-label · Prevention | Phase 4 | Completed | Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS) | De Novo Kidney Transplantation | 144 | Jul 2005actual | 2011-01-31 |
| Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME in Eldery de Novo Renal Transplant Recipients Treated With Basiliximab and Short-term SteroidsNCT00239031The 6-month study values of creatinine clearance, as calculated according to Cockcroft and Gault, summarized and compared between treatment groups.Randomized · Open-label · Prevention | Phase 3 | Completed | Drug: Enteric-Coated Mycophenolate Sodium | Denovo Renal Transplantation | 117 | Jul 2005actual | 2011-01-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19